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Head and neck squamous cell carcinoma (HNSCC) is characterized by 
immunosuppression, a state in which the established tumor evades the immune response. 
This presents a significant obstacle for treatment and the five-year survival rate for head 
and neck cancer patients remains at approximately 50%. While HNSCC causes profound 
immune inhibition, the immune changes that occur before HNSCC becomes established, 
at the premalignant lesion stage, are unknown. This study used the 4-nitroquinoline 
1-oxide (4-NQO) mouse model of oral carcinogenesis to investigate how the immune 
environment changes as premalignant lesions progress to tumor. Premalignant lesion-
bearing tongue tissue was found to release increased levels of Th1- and Th17-associated 
cytokines, including IL-2, IFN-γ, TNF-α and IL-17A, compared to control and 
HNSCC-bearing tongue tissue. Spleen cells and cervical lymph node cells produced 
increased levels of Th1- and Th2-associated cytokines in the presence of premalignant 
lesion-bearing tongue tissue compared to HNSCC-bearing tongue tissue. Premalignant 
lesion cells secreted significantly increased levels of proinflammatory G-CSF, RANTES, 
MCP-1, and PGE2 compared to HNSCC cells. Premalignant lesion cell supernatant 
elicited increased production of innate proinflammatory mediators and Th1- and 
Th17-associated cytokines from spleen cells compared to HNSCC cell supernatant or 
media alone. An increased percentage of spleen cells expressed markers of activation in 
the presence of premalignant lesion cell supernatant compared to HNSCC cell 
supernatant or media alone. This data shows that premalignant lesion cells release 
increased levels of proinflammatory mediators compared to HNSCC cells, and 
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furthermore, elicit increased production of Th1- and Th17-associated cytokines and 
expression of activation markers in spleen cells compared to HNSCC cells. Compared to 
the HNSCC environment, the premalignant lesion environment is significantly more 
immune stimulatory, supporting a robust Th1- and Th17-associated immune response.  
Immunosuppression is a significant obstacle to treatment for advanced HNSCC 
patients. The tumor itself plays a role in establishing this local and systemic 
immunosuppression, by secreting mediators such as PGE2 that decrease T cell-mediated 
immunity and support immunosuppressive cells at the tumor site. This study aims to 
determine if inhibition of PGE2 production at an earlier stage of carcinogenesis, the 
premalignant lesion stage, can restore a beneficial immune response and slow progression 
to tumor, in the 4-NQO mouse model of oral carcinogenesis. Initial studies showed that 
inhibition of PGE2 production by premalignant lesion cells (but not HNSCC cells) 
induced increased production of the Th1-associated cytokine IL-2 and IFN-γ by spleen 
cells in vitro. To monitor the effects of inhibiting PGE2 production in vivo, indomethacin, 
a COX (cyclooxygenase) inhibitor, was administered to mice bearing 4-NQO-induced 
premalignant lesions and progression to tumor was monitored by endoscopy. Mice 
receiving indomethacin at the premalignant lesion stage had significantly improved 
clinical outcomes compared to mice receiving diluent control treatment, as defined by 
lower lesion scores. Cervical lymph node analysis showed an increased percentage of 
CD8+ T cells expressing IFN-γ at the endpoint of the study (20 weeks) in mice that had 
received indomethacin compared to mice that had received diluent control treatment, 
although the difference was not significant. Spleen cells from mice that had received 
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indomethacin secreted increased levels of IFN-γ at 6 weeks and 20 post-treatment 
compared to mice that had received control treatment, suggesting that indomethacin 
treatment induced an increased systemic Th1-type immune response. The data suggests 
that the premalignant state is characterized by an immune stimulatory and inflammatory 
milieu and that inhibiting PGE2 production stimulates immune reactivity and slows 
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CHAPTER 1: IMMUNE REACTIVITY AND HNSCC 
1.1 An Introduction to Head and Neck Squamous Cell Carcinoma (HNSCC) 
1.1.1 Development of HNSCC 
Head and neck squamous cell carcinoma (HNSCC) accounts for over 90% of all 
head and neck cancers, with approximately 550,000 cases diagnosed each year 
worldwide [1, 2]. The major risk factors are tobacco and alcohol abuse, which have a 
synergistic effect on disease progression. HNSCC arises from keratinizing epithelial cells 
in the mucosa throughout the head and neck region, including the lip, oral cavity, nasal 
cavities, paranasal sinuses, pharynx and larynx. The development of HNSCC begins with 
the formation of leukoplakias or erythroplakias which, if left untreated, progress to 
carcinoma in situ and, finally, invasive carcinoma [3]. Because of the aggressive nature 
of the disease, the five-year survival rate for head and neck cancer patients remains 
around 50%, despite some advances in treatment over that last 30 years. A significant 
complication for treatment is that patients typically present with advanced tumors, which 
drastically reduces the effectiveness of traditional treatment strategies, including surgical 
resection and a combination of chemotherapy and radiation. In addition to having limited 
success, current treatment options greatly diminish patient quality of life, contributing to 
salivary gland hypofunction, xerostomia, bacterial infections, inflammation of the 
mucous membranes, and in some cases, malnutrition and dehydration due to the patient’s 
inability to eat and drink [4]. A majority of patients presenting with advanced tumors 
relapse locoregionally and/or at distant sites after initial treatment, at which point 
treatment by surgery, if possible, and reirradiation are significantly less successful [5-7].  
 Immune Changes Associated with Progression of Premalignant Lesions to HNSCC  
Chapter 1 3                            Introduction: Immune Reactivity   
                                                                                                                     and HNSCC 
1.1.2 Complications to Current Treatment Options 
Advanced HNSCC tumors use a variety of mechanisms to evade the host immune 
response and promote immunosuppression, presenting perhaps the most important 
obstacle for effective treatment and contributing to the high recurrence rate of this 
disease. HNSCC patients are characterized by systemic immunosuppression, exhibiting 
increased populations of regulatory T cells and CD34+ progenitor cells, which suppress 
CD8+ T cell- and CD4+ helper T cell-mediated immunity at the primary tumor site and 
are associated with a poorer prognosis [8-11]. Increased levels of CD127lo/- regulatory T 
cells in HNSCC patients are associated with more advanced malignancies involving local 
lymph nodes [12]. Similarly, increased levels of CD34+ progenitor cells are associated 
with increased tumor recurrence and metastasis [10]. While some immunotherapies, 
including IL-2/Interferon-gamma (IFN-γ) cytokine therapies and cetuximab/ 
nimotuzumab anti-epidermal growth factor receptor (EGFR) therapies have been shown 
to increase lymphocyte infiltration, prevent tumor progression and increase long-term 
survival when used in combination with standard treatment, responses vary greatly 
among patients and are often associated with significant toxicity [13-17]. Furthermore, 
some discrepancies in immune vs. clinical responses have been observed in trials with the 
anti-EGFR antibody nimotuzumab, in which clinical responses were not associated with 
significant lymphocyte activation [15]. A gap remains in our understanding of how 
HNSCC patients respond to immunotherapies since the immune changes that take place 
during the progression of HNSCC and how the tumor evades an effective immune 
response have not been completely mapped out. 
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1.2 Evasion of Immune Response by HNSCC Tumors 
1.2.1 Immune Escape in HNSCC 
It is well established that HNSCC tumors are associated with immune escape. The 
process of immunoediting is harnessed by many different types of tumors and generally 
begins with elimination, in which patrolling T helper cells recognize an invasive growth 
and send inflammatory signals to recruit natural killer (NK), NK T cells, macrophages, 
and dendritic cells to the site of the dysplastic tissue to mount an initial response [18]. 
During this stage, NK cells and antigen-presenting cells are transactivated by IFN-γ and 
IL-12 secretion and tumor cells are eliminated by TNF-related apoptosis-inducing ligand 
(TRAIL), perforin, and reactive nitrogen species. Tumor-specific CD4+ and CD8+ T cells 
begin to hone to the developing tumor as well, initiating the adaptive antitumor response 
[18]. The second stage of immunoediting is characterized by a dynamic equilibrium 
between the developing tumor bed and the host’s immune system, and may last up to 
several years. During this stage, IFN-γ- producing CD4+ and CD8+ T cells are unable to 
completely eliminate the rapidly dividing/mutating HNSCC tumor cells. During the final 
stage of immunoediting, tumor escape, HNSCC tumor cells decrease antigen, major 
histocompatibility complex (MHC) I/II and costimulatory molecule expression to directly 
thwart an effective immune response [19-23]. In addition, by upregulating death ligands 
such as FasL and PD-L1, HNSCC tumors trigger apoptosis in infiltrating lymphocytes, 
further dampening the immune response at the tumor site [24, 25]. Infiltrating 
immunosuppressive populations, including myeloid-derived suppressor cells (MDSCs) 
and T regulatory cells, contribute to tumor-associated immunosuppression by directly 
inhibiting CD8+ T cell-mediated immunity and promoting tumor growth [1, 12, 26]. 
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1.2.2 Immune Environment of HNSCC 
A significant complication of understanding how the tumor contributes to 
immunosuppression is the complex network of tumor cells, fibroblasts, 
carcinoma-associated fibroblasts (CAFs), smooth muscle cells, endothelial cells, and 
myriad of tumor-infiltrating immune populations including tumor-associated 
macrophages, B cells, T cells and antigen-presenting cells that make up the tumor 
microenvironment [27]. One of the major mechanisms by which HNSCC tumors are 
thought to evade host immune recognition is by modulating the cytokine environment at 
the tumor site. By secreting cytokines such as IL-6 and IL-10, HNSCC tumor cells 
promote a T helper cell type 2 (Th2)-skewed response, which is associated with 
decreased antitumor efficacy [20, 28]. This Th2-skewing is also evident systemically, as 
peripheral blood mononuclear cells (PBMCs) isolated from advanced HNSCC patients 
secrete abnormally high levels of Th2 cytokines [29, 30]. Along with Th2-skewed 
cytokines, HNSCC tumors secrete increased levels of immunosuppressive factors such as 
transforming growth factor-beta (TGF-β) that function to directly inhibit cytotoxic T 
cell-mediated immunity and recruit immunosuppressive cells, including MDSCs and 
M2-skewed macrophages, to the tumor site [31, 32]. Once at the tumor site, HNSCC 
tumor cells harness these immunosuppressive cells for a myriad of tumor-promoting 
functions, including increased growth and angiogenesis. HNSCC cells trigger increased 
IL-6 production from CD34+ progenitor cells, for example, promoting angiogenesis in the 
tumor microenvironment [33].  
HNSCC tumors also secrete factors that are typically associated with a 
proinflammatory response, harnessing these immune modulators to favor growth, 
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angiogenesis and paradoxically, immune escape. Several of these mediators have also 
been shown to recruit immunosuppressive cells to the tumor site. Granulocyte-
macrophage colony-stimulating factor (GM-CSF) and prostaglandin E2 (PGE2), which 
have traditional proinflammatory roles that support the differentiation of macrophages 
and neutrophils in the early stages of inflammation, are significantly increased in the 
supernatant of primary SCC lines from patients with head and neck cancer [34]. 
Tumor-secreted GM-CSF has been shown to promote MDSC recruitment and 
differentiation, and high levels of GM-CSF in HNSCC patients are associated with a 
poorer prognosis [10, 35]. Increased levels of PGE2 are associated with invasion and 
angiogenesis in aggressive early-stage tumors [36]. Other factors secreted by HNSCC 
tumors, including monocyte chemotactic protein-1 (MCP-1), have been shown to 
contribute to immunosuppression at the tumor site by recruiting a population of IL-10 
and TGF-β-secreting M2 skewed tumor-associated macrophages [37]. By secreting a host 
of immune modulators, HNSCC tumors thwart an effective immune response and 
become increasingly difficult to treat.  
1.3 Role of Prostaglandin E2 in HNSCC 
1.3.1 Role of PGE2 in Cancer  
The role of PGE2 in tumor progression has not been clearly defined. One reason 
for this is that PGE2 is produced by a myriad of cell types, including epithelial cells, 
fibroblasts, infiltrating immune cells and cancer cells, all of which comprise/surround a 
developing tumor [38]. Furthermore, the role of PGE2 seems to shift during tumor 
progression. During early stages of inflammation, PGE2 has been shown to promote the 
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infiltration of neutrophils, macrophages and mast cells [39-41]. However, PGE2 has been 
shown to have an inhibitory effect on granulocyte function and macrophage 
phagocytosis, contributing to defective innate immunity in cancer patients and patients 
who have undergone bone marrow transplantation [38, 42-45]. PGE2 also inhibits several 
arms of adaptive immunity. It has been shown to directly inhibit IL-2 production by T 
cells, decrease IL-2 responsiveness and suppress antigen-specific T cells [46, 47]. Several 
studies have shown that PGE2 disrupts normal dendritic cell differentiation and 
suppresses the activity of T helper cell type 1 (Th1)-associated dendritic cells (DCs), 
resulting in decreased IL-12 production and Th2 skewing of mature T helper cells [48-
51]. These PGE2-skewed DCs, or MDSCs, have been shown to the suppress cytotoxic T 
cell responses, skew macrophage differentiation towards the pro-tumor M2 phenotype 
and contribute to overall dendritic cell dysfunction in the cancer setting [52-55]. 
However, the effect of PGE2 on mature dendritic cells is more immune stimulatory. PGE2 
promotes the surface expression of chemokine receptor 7 (CCR7) and costimulatory 
molecules, contributing to DC migration to lymph nodes and their subsequent activation 
[49, 56-59]. All in all, the role of PGE2 on immune function is complex and there remains 
a gap in our knowledge of how PGE2 contributes to tumor progression.  
1.3.2 PGE2 and COX Inhibitors in HNSCC 
It is well established that arachadonic acid metabolism is altered in established 
HNSCC tumors. COX-2, the inducible enzyme involved in PGE2 production, is 
significantly upregulated in HNSCC tumors and increased levels of PGE2 are associated 
with decreased levels of CD8+ T cells and increased levels of suppressor cells at the 
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tumor site [20, 26, 28, 60]. Preliminary studies have shown that inhibiting COX-2 leads 
to increased apoptosis and decreased angiogenesis of HNSCC cells, both in vitro and in 
vivo [61]. In several murine and hamster models of head and neck cancer, administration 
of the COX-2 inhibitor celecoxib to animals with tumors resulted in decreased tumor 
expression of vascular endothelial growth factor (VEGF) and survivin, increased tumor 
cell apoptosis, and decreased tumor growth [61-63]. However, the impact of 
administering a COX inhibitor before tumors become established, at the premalignant 
lesion stage, has not been previously investigated.   
COX-2 inhibitors are being explored as a possible adjuvant to traditional therapies 
in head and neck cancer treatment. In one study of head and neck cancer patients, 
preoperative administration of the COX-2 inhibitor Rofecoxib resulted in restored 
monocyte function and migration, suggesting that inhibiting COX-2 may be a key 
strategy in restoring immune function [64]. One retrospective study looking at the 
relationship between the use of nonselective cyclooxygenase inhibitors and overall 
survival in HNSCC patients found that median survival was increased among COX 
inhibitor users, although the regimen/type of COX inhibition was not controlled for in 
this study [65]. In several clinical trials, administration of celecoxib as an adjuvant 
therapy for head and neck cancer patients has been associated with significant response 
rates [66-68]. However, the mechanism by which COX-2 inhibition may be altering the 
immune response in HNSCC patients has not been extensively explored.  
Some of the mechanisms by which PGE2 may be modulating the immune 
response in other types of malignancies, including colorectal, lung, and breast cancers, 
 Immune Changes Associated with Progression of Premalignant Lesions to HNSCC  
Chapter 1 9                            Introduction: Immune Reactivity   
                                                                                                                     and HNSCC 
are starting to be defined. Several studies have shown that PGE2 induces the production 
of IL-10 and directly suppresses the production of proinflammatory cytokines by CD4+ T 
cells, implicating it as a key player in tumor-associated immunosuppression [26, 38, 69, 
70]. In a model of lung carcinoma, inhibition of COX-2 resulted in increased antitumor 
reactivity by shifting the cytokine balance of resident immune cells towards a more 
proinflammatory, Th1-like phenotype, as characterized by increased IL-12 production 
and decreased IL-10 production [71]. The role of PGE2 in modulating the immune 
response in head and neck cancer—and specifically what role PGE2 plays as 
premalignant lesions progress to HNSCC tumors—has not been previously investigated 
and is the focus of Specific Aim 2 of this dissertation.  
1.4 Premalignant Lesions  
1.4.1 Immune Environment of Premalignant Lesions  
 A critical gap that remains in head and neck cancer research is the progression of 
premalignant lesions to established HNSCC. There has been little focus on the 
premalignant state of HNSCC, and the molecular and immunological conditions that 
foster development into established HNSCC. A major challenge is that patients typically 
present with more advanced tumors, so studies on the premalignant lesion state are less 
complete. In one study, premalignant lesion tissue extracted from patients secreted 
increased levels of Th1-associated IL-2 and IFN-γ and T helper cell type 17 
(Th17)-associated IL-17A compared to HNSCC tissue and normal oral tissue [72]. 
Premalignant lesion tissue also released increased levels of pro-inflammatory IL-6 
compared to HNSCC tissue and healthy oral tissue [72]. This study shows that
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premalignant lesion tissue is more proinflammatory than HNSCC tissue and suggests that 
it may be more immune stimulatory compared to the established tumor. The immune 
changes observed at the site of the premalignant lesion or HNSCC tumor do not 
necessarily reflect changes in the immune response systemically. In the same study, 
levels of IL-2 and IFN-γ were not increased in the plasma of patients bearing 
premalignant lesions compared to HNSCC and control patients [72]. IL-17A, however, 
was increased in the plasma of patients bearing premalignant lesions compared to 
HNSCC and control patients, reflecting what was observed in premalignant lesion tissue 
[72]. Several studies have shown that IL-6 and tumor necrosis factor-alpha (TNF-α) were 
increased in the saliva of patients with premalignant oral lesions compared to control 
patients [73, 74], suggesting that a local inflammatory response occurs in the oral cavities 
of patients with developing lesions. Premalignant oral lesion epithelium has been shown 
to expresses several proinflammatory molecules, including TNF-α, stromal cell-derived 
factor 1 (SDF-1 or CXCL12), and the toll like receptors TLR4 and TLR9, which promote 
an inflammatory immune response [75-77].   
Another difficulty in understanding the premalignant lesion environment is the 
complex network of epithelial cells, fibroblasts, endothelial cells, muscle cells, and 
infiltrating immune cells that make up the developing lesions. The contribution of 
inflammatory immune cells vs. resident cells such as endothelial cells and fibroblasts to 
the proinflammatory milieu of premalignant lesions is not always straightforward. 
Several studies have shown that premalignant lesions are characterized by an influx of 
proinflammatory immune cells, including NK cells, macrophages, and CD8+ T cells [78, 
79]. In these studies, the infiltration of NK cells and CD8+ T cells into premalignant 
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lesions correlated with the degree of dysplasia [78, 79]. Dendritic Langerhans cells were 
also found to be increased in leukoplakias with dysplasia and were co-localized with T 
cells in many cases [78, 79]. There is evidence that CD8+ T cells are more activated in 
premalignant lesions, as they have been shown to express increased levels of granzyme B 
and perforin in premalignant lesion tissue vs. in control tissue [80]. Endothelial cells also 
play a role in modulating the immune environment of premalignant lesions through their 
production of VEGF, PGE2, IL-6, and TGF-β [81-83]. These factors recruit immune cells 
into premalignant lesions and also modulate their activity once at the site of the 
developing lesions. Because lesions are composed of such a complex network of cells 
and patients rarely present with such an early stage of disease, there remains a critical gap 
in our knowledge of the immune environment of premalignant lesions, and how 
premalignant lesion cells themselves, may be modulating the immune response.    
1.4.2 4-NQO Mouse Model of Oral Carcinogenesis 
The 4-NQO mouse model produces all stages of oral carcinogenesis and allows 
careful observation of the immune environment as premalignant lesions progress to 
HNSCC. This model is based on the carcinogenic effects of 4-NQO, which can be 
administered in the drinking water of C57BL/6 mice and mimics the effects of tobacco, a 
major risk factor for HNSCC [84, 85]. Other models of HNSCC, including the xenograft 
model in which human HNSCC cells are injected subcutaneously or into the mylohyoid 
muscle of the mouse oral cavity, do not allow for the study of multistep carcinogenesis or 
the contribution of the immune system on the progression of HNSCC from the 
premalignant state to established tumor. In addition, because injected tumor cells do not 
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originate from the epithelium of the head and neck region, the molecular changes that 
occur as normal epithelium becomes dysplastic cannot be tracked [86-88]. The 
7,12-dimethylbenz[a]anthracene (DMBA) Syrian hamster cheek model induces 
premalignant oral lesions with genetic/epigenetic alterations that mimic human HNSCC, 
but because humans do not have an anatomic pouch, these tumors do not resemble human 
tumors anatomically or histologically [89-91].   
The 4-NQO model of oral carcinogenesis induces the formation of premalignant 
oral lesions that progress to exophytic, HNSCC tumors. At the molecular level, 4-NQO 
causes the formation of reactive oxygen species (ROS), DNA adducts (adenosine to 
guanosine substitutions) and H-ras mutations, mimicking the DNA damage induced by 
tobacco and alcohol use, and therefore modeling human disease at the molecular level 
[92-94]. One of the strengths of the 4-NQO model is that 4-NQO is a water-soluble 
quinoline derivative that can be administered in the drinking water, so the mice are 
constantly exposed to the carcinogen, as a model human disease [95, 96].  The most 
relevant strength of the 4-NQO model is that it allows the immune response to be studied 
as premalignant lesions progress to HNSCC tumors. Administration of 4-NQO in the 
drinking water at a concentration of 50 μg/mL results in the formation of premalignant 
lesions on the tongue at 6-8 weeks, which progress to more exophytic, malignant tumors 
by 12-16 weeks. Because tumors formed in this model of oral carcinogenesis closely 
mimic HNSCC tumors in human patients at both the histological and molecular levels, 
the 4-NQO model is an ideal candidate for immunotherapy studies [95, 97-99].  
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1.4.3 Changes in the Immune Response as Premalignant Lesions Progress to 
HNSCC  
 
Initial studies using the 4-NQO mouse model of oral carcinogenesis offer some 
insight into the immune changes that take place during the development of HNSCC. To 
investigate the immune response against developing oral tumors, these studies focused on 
immune cell infiltration into the tumor-draining, cervical lymph nodes of mice with 
4-NQO-induced oral lesions and 4-NQO-induced established tumors. These studies 
showed that tumor-draining lymph nodes of HNSCC-bearing mice are characterized by 
an increase in the percentage and absolute number of CD4+Foxp3+ regulatory T cells 
compared to lymph nodes of premalignant lesion-bearing and control mice, 
demonstrating that there is increased infiltration of immunosuppressive cells in the 
established tumor state [100]. This mirrors the increase in T regulatory cells observed 
both in the periphery and in the tumors of HNSCC patients, supporting the 4-NQO model 
as a closely representative model of human disease [8-12]. In contrast, cervical lymph 
nodes of premalignant lesion-bearing mice are characterized by an increased percentage 
and absolute number of proinflammatory Th17 cells compared to lymph nodes of 
HNSCC-bearing mice and control mice, suggesting that the premalignant lesion state is 
proinflammatory but as the lesion progresses to tumor, the immune response wanes and 
immunosuppressive cells dominate. While the absolute numbers of conventional CD4+ 
and CD8+ T cells are increased in the cervical lymph nodes of HNSCC-bearing mice 
compared to that in premalignant lesion-bearing and control mice, conventional CD4+ T 
cells isolated from the cervical lymph nodes of HNSCC-bearing mice were characterized 
by decreased proliferation and secreted decreased levels of IL-2 upon stimulation in vitro 
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compared to T cells isolated from control mice [100]. Taken together, these data showed 
that conventional CD4+ T cells isolated from mice bearing established HNSCC tumors 
are functionally compromised compared to T cells isolated from control mice and, to 
some extent, premalignant lesion-bearing mice as well. These studies suggest that the 
tumor environment may be more immune inhibitory compared to the premalignant lesion 
environment. Future studies are necessary to determine how the immune response 
evolves from the premalignant lesion to established HNSCC and how this impacts on 
tumor progression. 
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CHAPTER 2: RATIONALE, HYPOTHESIS, AND SPECIFIC AIMS 
2.1 Rationale 
It is well established that advanced HNSCC is associated with local and systemic 
immunosuppression. Previous studies have shown that HNSCC tumors produce several 
immune inhibitory factors, including TGF-β and PGE2, which recruit immunosuppressive 
cells and directly inhibit T cell function at the tumor site [8, 10, 11, 19, 20, 28, 31, 32, 
70]. However, much less is known about factors produced by premalignant lesions, and 
how the immune environment shaped by premalignant lesions impacts on the immune 
response as lesions progress to tumor. A few patient studies have suggested that 
premalignant lesions are more proinflammatory, characterized by increased production of 
IL-6 and IL-17A, compared to HNSCC tumors [72-74]. Preliminary studies using the 
4-NQO mouse model of oral carcinogenesis have shown that immune cells infiltrating the 
lymph nodes draining premalignant lesions are more activated and produce higher levels 
of proinflammatory cytokines (IL-17A) compared to immune cells infiltrating the 
cervical lymph nodes of HNSCC-bearing mice [100]. Taken together, these data suggest 
that immune environment of the premalignant lesions may be more immune stimulatory 
than in the tumor environment. But little is known about the immune mediators produced 
by premalignant lesion cells themselves, and how these mediators impact on immune cell 
function at this stage.  
Traditional treatment options for HNSCC patients, including surgery and 
chemotherapy/radiation, are not successful in the majority of cases and the 5 year 
survival rate for this disease remains less than 50% [2]. A major obstacle to treatment is 
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the immunosuppressed state of HNSCC patients. While immunotherapies have been 
successful in some cases, overall these therapies are not widely effective and many are 
associated with considerable toxicity. Our lab is interested in modulating the immune 
response at the premalignant lesion stage as a means to stimulate the antitumor response. 
One mediator that is known to promote immunosuppression in the HNSCC environment 
is PGE2. HNSCC tumors directly secrete PGE2 and while the immune effects of PGE2 in 
the tumor environment are not completely mapped out, increased levels of PGE2 have 
been correlated with decreased T cell function, increased infiltration of MDSCs, and a 
worse prognosis in patients [20, 26, 28, 60, 69, 70]. The role of PGE2 in the premalignant 
environment remains unknown. Our preliminary studies have shown that premalignant 
lesion cells produce PGE2 in significantly higher levels than HNSCC cells [101]. This 
suggests that PGE2 may be modulating the immune response at a much earlier stage of 
disease than has been previously appreciated and inhibition of PGE2 at this stage may 
lead to a greater immunity against tumor. After defining the immune milieu of 
premalignant lesions, our goal is to understand how PGE2 impacts on the immune 
response in the premalignant lesion environment and then to inhibit PGE2 production at 
the premalignant lesion stage to sustain a Th1-type response and slow progression to 
tumor.  
2.1.1 Hypothesis  
Our hypothesis is that the premalignant lesion environment is highly proinflammatory, 
which supports a robust immune response, but as the tumor becomes established, the 
immune environment becomes less immune stimulatory, resulting in decreased 
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Th1-mediated immune responses. We also hypothesize that PGE2 is a key player in 
skewing the immune stimulatory environment of the premalignant lesion to the 
immunosuppressive environment of the HNSCC tumor and COX inhibition at the 
premalignant lesion stage will sustain Th1-mediated responses and slow progression to 
tumor. 
2.1.2 Specific Aims 
This hypothesis will be tested through the following specific aims: 
Aim 1: To investigate how the immune environment changes as premalignant 
lesions progress to tumor and how the evolution of the immune environment 
impacts on immune cell activation and function in the 4-NQO mouse model of oral 
carcinogenesis.  
HNSCC tumors are known to secrete factors such as TGF-β and PGE2 that 
dampen the immune response at the site of the tumor, and contribute to the 
immunosuppression of established HNSCC. Considerably less is known about the 
environment of premalignant lesions. The focus of this aim is to define the premalignant 
lesion environment in the 4-NQO model and to determine how factors produced by 
premalignant lesion cells impact on immune cell cytokine production and activation.  
Aim 2: To prevent the immune skewing and tumor progression in 4-NQO-treated 
mice by inhibiting PGE2 production at the premalignant lesion stage. 
In the tumor environment, PGE2 is known to inhibit an effective antitumor 
response in a number of ways, including recruitment of immune inhibitory cells and 
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inhibition of conventional T cell function. Inhibition of PGE2 production has been shown 
to promote a more active immune response and lead to increased survival in HNSCC 
patients. Our preliminary studies show that premalignant lesion cells produce high levels 
of PGE2. The focus of this aim is to understand how PGE2 modulates the immune 
response in the premalignant lesion environment and how inhibiting PGE2 production at 
this stage impacts on immune cell function and tumor progression.   
2.2 Significance 
 Head and neck cancer is the sixth most common cancer worldwide, with an 
overall survival rate that remains below 50%. Patients often present with advanced 
tumors and systemic immunosuppression, making treatment very challenging. Many 
studies have focused on factors secreted by HNSCC tumors and how they contribute to 
immunosuppression, both at the tumor site and systemically. Factors such as TGF-β and 
PGE2 lead to decreased T cell reactivity at the tumor site and also modulate the activity of 
systemic immune cells, skewing them to a Th2 phenotype and inhibiting an effective 
antitumor response. It is evident that mediators produced by tumor cells play a 
considerable role in controlling immunity. Therefore, therapies that activate the immune 
response in patients at high risk of developing HNSCC may prove to be more effective as 
adjuvant treatments to surgery or photodynamic therapies, or even as primary treatments 
to prevent progression of lesions to cancer.    
What is not evident is how mediators produced by premalignant lesion cells 
impact on the immune response. One reason for this is a lack of studies focusing on 
patients with premalignant lesion disease and the other is a focus on animal models that 
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have primarily advanced disease. Our lab is interested in the immune response at the 
premalignant lesion stage, and how the response changes as premalignant lesions 
progress to HNSCC. The 4-NQO mouse model of oral carcinogenesis is ideal because it 
produces all stage of oral carcinogenesis and is based on the effects of 4-NQO, a 
carcinogen that induces DNA damage and models the effects of tobacco at the molecular 
and histological levels. Our primary focus is to isolate premalignant lesion cells and 
evaluate how factors produced by these cells impacts on immune cell activation and 
function, compared to HNSCC cells. This model allows us to directly compare the 
premalignant lesion and HNSCC environments, and tease apart the contribution of each 
cell type to immune reactivity. Preliminary studies have shown that premalignant lesion 
cells themselves produces high levels of PGE2. Although PGE2 is known to contribute to 
immunosuppression in established HNSCC, its role in the premalignant lesion 
environment is not defined. The 4-NQO model allows us to administer the COX inhibitor 
indomethacin at the premalignant lesion stage to better understand the role of PGE2 in 
modulating the immune response at this stage and to track how COX inhibition impacts 
on tumor progression. By understanding how the immune response changes as 
premalignant lesions progress to tumor, we can better tailor immunotherapies to promote 
an effective antitumor response. 
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CHAPTER 3: EFFECT OF THE PREMALIGNANT LESION AND HNSCC 
ENVIRONMENTS ON IMMUNE CELL REACTIVITY 
 
Aim 1: To investigate how the immune environment changes as premalignant 
lesions progress to tumor and how the evolution of the immune environment 




HNSCC accounts for over 90% of all head and neck cancers and, despite some 
advances in treatment over the last 30 years, the five-year survival rate remains around 
50% [1, 2]. HNSCC patients are characterized by systemic immunosuppression, 
exhibiting increased populations of regulatory T cells and CD34+ progenitor cells, which 
suppress CD8+ T cell- and CD4+ helper T cell-mediated immunity at the primary tumor 
site and are associated with a poorer prognosis [8-12]. By evading the immune response, 
HNSCC tumors become increasingly difficult to treat and are also characterized by a high 
recurrence rate.  
Several of the ways in which HNSCC tumors evade the host immune response 
have been defined. Over the course of immune escape, HNSCC cells lose MHC and 
costimulatory molecule expression and secrete immune inhibitory factors such as TGF-β 
and PGE2, inhibiting an effective cytotoxic T cell response and allowing the tumor to 
persist [19-22, 26, 31, 32, 60]. HNSCC tumors also secrete factors that are typically 
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associated with a proinflammatory response, harnessing these immune modulators to 
favor growth, angiogenesis and, paradoxically, immune escape. GM-CSF and MCP-1, 
which have traditional proinflammatory roles that support the differentiation of 
macrophages and neutrophils in the early stages of inflammation, are significantly 
increased in the supernatant of primary SCC lines from patients with head and neck 
cancer and have been shown to promote MDSC recruitment and differentiation as well as 
M2 macrophage polarization [10, 35, 37]. Secretion of these factors by HNSCC tumors 
has been correlated with patient prognosis. High levels of GM-CSF in HNSCC patients 
are associated with a poorer prognosis and increased levels of PGE2 are associated with 
invasion and angiogenesis in aggressive early-stage tumors [10, 20, 36, 60]. These studies 
indicate that factors secreted by HNSCC tumors play a direct role in modulating a 
patient’s immune response, which plays a critical role in their prognosis and treatment 
options.  
There remains a critical gap in our understanding of the immune changes that 
occur before HNSCC becomes established, at the premalignant lesion stage. One study 
analyzing tissue from patients with premalignant oral lesions, showed that premalignant 
lesion tissue releases increased levels of several proinflammatory cytokines, including 
IL-2, IFN-γ, and IL-17A, compared to HNSCC tissue [72]. Preliminary studies using the 
4-NQO mouse model of oral carcinogenesis have shown that the cervical lymph nodes of 
premalignant lesion-bearing mice are characterized by an increased percentage of 
activated T cells and increased levels of proinflammatory cytokines, including IL-17A 
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[100]. These data suggest that an active immune response is taking place in the 
preneoplastic stage and that this response is thwarted once the tumor becomes 
established. However, the mediators released directly by premalignant lesion cells 
themselves and how they impact on the immune response as the tumor becomes 
established remains unknown.  
     The current study uses the 4-NQO mouse model to define the immune 
environment of premalignant lesions at both the tissue and cellular levels, and to 
determine how soluble mediators from cells established from carcinogen-induced oral 
premalignant lesions and HNSCC tumors impact on immune cell activation and function. 
Premalignant lesion-bearing tongue tissue was defined by increased Th1- and Th17-
associated cytokines compared to both HNSCC-bearing and control tongue tissue. 
Premalignant lesion cells, themselves, secreted high levels of several proinflammatory 
mediators, including G-CSF, RANTES, MCP-1, and PGE2. To determine how the 
premalignant lesion and HNSCC environments modulate immune cell function and 
activation, spleen cells from control C57BL/6 mice were cultured with media conditioned 
by premalignant lesion cell-conditioned media or HNSCC cell-conditioned media. 
Results of these studies showed that in the presence of premalignant lesion cell-
conditioned media, spleen cells produced significantly increased levels of Th1-, Th2- and 
Th17-associated cytokines and an increased percentage of CD8+ T cells expressed the 
activation marker CD69+, compared to spleen cells in the presence of HNSCC 
cell-conditioned media or media alone. Premalignant lesion cell-conditioned media also 
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elicited increased production of Th1-, Th2-, and Th17-associated cytokines from cervical 
lymph node cells compared to HNSCC cell-conditioned media. Overall, these studies 
showed that the premalignant lesion environment was more proinflammatory and elicited 
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3.2 Materials and Methods 
Oral HNSCC carcinogenesis 
Five mg/mL 4-NQO in propylene glycol stock was diluted into the drinking water 
at a final concentration of 50 μg/mL and administered to 2-month-old female C57BL/6 
mice (Charles Rivers Laboratory, Wilmington, MA, USA) until the development of 
premalignant oral lesions (6–8 weeks) or HNSCC (12–16 weeks). To monitor lesion 
development, mice were examined endoscopically weekly using a Stryker 1.9 mm × 30° 
endoscope and images were taken using a Stryker 1088 camera (Kalamazoo, MI, USA). 
During the procedure, mice were sedated with inhaled isoflurane (Piramal Healthcare, 
Boise, ID, USA).  
 
Tongue processing and culture  
After extraction, each tongue was minced and enzymatically digested using 100 
μg/mL of complete liberase cocktail (Roche, Indianapolis, IN, USA) in 10 mL Hank’s 
Buffered Saline Solution (HBSS, Life Technologies, Grand Island, NY, USA) at 37º C 
for 4 h. Tissue was plated overnight in 12-well tissue culture plates (one dissociated 
tongue/well) in Dulbecco’s Modified Eagle Media (DMEM) supplemented with 10% 
FBS and penicillin/streptomycin/amphotericin B at 37° C. Tissue was restimulated with 2 
μl/mL Cell Stimulation Cocktail (eBioscience) consisting of phorbol myristate acetate 
(PMA) and ionomycin for the last 4-6 h of culture at 37º C and supernatant was collected 
for cytokine/chemokine analysis. For each dissociated tongue, cytokine/chemokine levels 
were standardized to total protein. To measure total protein, tissue was collected, washed 
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with Dulbecco’s phosphate buffered saline (DPBS, Life Technologies, Grand Island, NY, 
USA), resuspended in 1 mL phosphate buffered saline (PBS) and lysed using an 
ultrasonic processor for 2 min. on ice. Total protein was quantitated using a BCA protein 
assay kit (Thermo Scientific, Rockford, IL, USA). 
 
Premalignant lesion and HNSCC cell lines  
Primary cell lines were established by excising the tongues of premalignant or 
HNSCC-bearing mice at the appropriate stage, as defined through histopathological analysis 
by the oral pathology section in the Center for Oral Health Research at the Medical 
University of South Carolina. Premalignant lesions or HNSCC were excised from the 
tongues of 4-NQO treated mice.  To establish cell lines, premalignant lesions or HNSCC 
tumors were washed several times with PBS and antibiotic/antimycotic solutions containing 
100 mg/mL penicillin, 100 mg/mL streptomycin, and 200 mg/mL neomycin. Premalignant 
lesions or HNSCC tumors were plated on 60 mm tissue culture dishes in DMEM media 
supplemented with 10% FBS and penicillin/streptomycin/amphotericin B and cultured for 
two weeks at 37º C, replacing the media twice per week. After this period, adhering 
premalignant lesion or carcinoma cells were removed and cultured in 75 cm2 flasks in fresh 
media at 37° C, replacing the media twice per week. Prior to defining cells as 
premalignant or HNSCC, their epithelial phenotype was confirmed as well as uniformity 
of their microscopic and growth characteristics. To detach adherent cells, they were 
trypsinized, washed, and resuspended in fresh medium. After cell lines were established, 
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supernatants were collected after 48 h of culture (when cells reached 80% confluence) for 
cytokine analysis.  
 
Cytokine bead array 
All reagents used for the cytokine bead array are from BD Biosciences unless 
otherwise specified. The levels of IFN-γ, IL-2, IL-17A, IL-4, IL-6 and IL-10 in cell or tissue 
cultures were determined using a mouse cytometric bead array (CBA) Th1/Th2/Th17 
cytokine kit. Levels of IL-1α, IL-1β, IL-13, IL-12p70, IL-9, GM-CSF, G-CSF, MIG, 
MCP-1, MIP-1α, MIP-1β and RANTES in cell or tissue cultures were determined using 
cytometric bead array flex sets for the individual cytokines according to the manufacturer’s 
instructions. A FACS Canto (BD Biosciences, San Jose, CA, USA) flow cytometer was 
used to quantify cytokine profiles and relative amounts of each cytokine were analyzed 
using FCAP Array Software (manufactured by Soft Flow Hungary Ltd. for BD 
Biosciences, San Jose, CA, USA). In experiments where premalignant lesion or HNSCC 
supernatants were added to spleen cell cultures, cytokine levels in total spleen cell 
supernatants were adjusted for baseline levels in premalignant or HNSCC supernatants.  
 
TGF-β1 ELISA 
To quantify TGF-β1 in cell supernatants, a sandwich ELISA was performed 
according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA). 
Before analysis, latent TGF-β1 was activated to immunoreactive TGF-β1 by addition of 
HCl solution, as described by the manufacturer. Premalignant lesion and HNSCC cell 
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supernatants were diluted 1:5 in sample diluent for analysis. Optical density at 450 nm 
was measured using a Spectra Max M2 plate reader. Concentration of TGF-β1 was 
determined using SoftMax Pro 5.4.2 plate reader software. A standard concentration 
curve was generated for each independent experiment. Samples were analyzed in 
duplicate for each of three independent experiments.  
 
Prostaglandin E2 ELISA 
To quantify PGE2 in cell supernatants, a competitive ELISA was performed 
according to the manufacturer’s instructions (Pierce Biotechnology, Rockford, IL, USA). 
Cell supernatants were diluted 1:2 for analysis. Optical density at 405 nm was measured 
using a Spectra Max M2 plate reader. Concentration of PGE2 was determined using 
SoftMax Pro 5.4.2 plate reader software. A standard concentration curve was generated 




Spleens were harvested from control C57BL/6 mice and homogenized using a 
glass homogenizer. Cells were passed through a 70 μm cell strainer (BD Falcon, San 
Jose, CA, USA) and rinsed with HBSS. Red blood cells were lysed by adding ACK 
Lysing Buffer (Lonza, Walkersville, MD, USA) for 3 min. Splenocytes were then washed 
twice with HBSS. Cell number was determined by counting cells excluding trypan blue 
using a hemocytometer.  
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Cervical lymph node processing  
Cervical lymph nodes were harvested from control C57BL/6 mice and 
homogenized using a Stomacher 80 homogenizer (Seward) set on high for 90 sec. Cells 
were then passed through a 70 μm cell strainer (BD Falcon, San Jose, CA, USA) and 
rinsed with HBSS. Cell number was determined by counting cells excluding trypan blue 
using a hemocytometer.  
 
Culture medium 
 Cell culture media consisted of 1X DMEM (Life Technologies, Grand Island, 
NY, USA) containing 4.5 g/L D-glucose and L-glutamine, supplemented with 10% fetal 
bovine serum (FBS, Sigma, St. Louis, MO, USA) and 1X antibiotic antimycotic solution 
(Sigma, St. Louis, MO, USA) containing penicillin, streptomycin and amphotericin B. To 
establish cell lines from premalignant lesions and HNSCC tumors, culture media was 
supplemented with 2X antibiotic antimycotic solution for the first 2 weeks of culture.  
 
Spleen cell cultures 
           Spleen cells were cultured in 12-well anti-CD3-coated tissue culture plates at 
1X106 cells/well in fresh media or media conditioned by premalignant lesions or HNSCC 
with IL-2 (R&D Systems, Minneapolis, MN, USA) for 72 hr at 37º C. Premalignant lesion 
cell and HNSCC cell supernatants were diluted 1:2 in fresh media for culture with spleen 
cells. Premalignant lesion-bearing and HNSCC tongue tissue supernatants were diluted 1:10 
in fresh media for culture with spleen cells. For spleen cell cytokine analysis, cells were 
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restimulated with 2 μL/mL Cell Stimulation Cocktail (eBioscience, PMA/ionomycin) for the 
last 4-6 h of culture at 37º C and supernatants were collected for analysis by CBA. For 
analysis of surface marker expression by flow cytometry, cells were gently collected 
from tissue culture plates with 25 cm cell scrapers (Sarstedt, Inc., Newton, NC, USA), 
washed once with stain buffer, and transferred to polystyrene tubes at 1X106 cells/tube 
for analysis by flow cytometry. For analysis of intracellular cytokine expression by flow 
cytometry, cells were restimulated with 2 μL/mL Cell Stimulation Cocktail (eBioscience, 
PMA/ionomycin) and 0.6 μL/mL GolgiStop (BDBiosciences) for the last 4-6 h of culture at 
37º C. Cells were gently collected from tissue culture plates with 25 cm cell scrapers 
(Sarstedt, Inc., Newton, NC, USA), washed once with stain buffer, and transferred to 
polystyrene tubes at 1X106 cells/tube for analysis by flow cytometry. 
 
Cervical lymph node cell cultures 
Cervical lymph node cells were cultured in 12-well anti-CD3-coated tissue culture 
plates at 1X106 cells/well in fresh media or media conditioned by premalignant lesions or 
HNSCC, with IL-2 (R&D Systems, Minneapolis, MN, USA)  for 72 hr at 37º C. 
Premalignant lesion cell and HNSCC cell supernatants were diluted 1:2 in fresh media for 
culture with lymph node cells. For cytokine analysis, cells were restimulated with 2 μL/mL 
Cell Stimulation Cocktail (eBioscience, PMA/ionomycin) for the last 4-6 h of culture at 37º 
C and supernatants were collected for analysis by CBA.   
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Flow cytometric analysis of spleen cells: surface markers  
All antibodies and reagents for this section are from BDBiosciences unless 
otherwise stated. Spleen cells were gently collected from tissue culture plates with 25 cm 
cell scrapers (Sarstedt, Inc., Newton, NC, USA), washed once with stain buffer, and 
transferred to polystyrene tubes at 1X106 cells/tube for flow cytometric analysis. Cells 
were resuspended in 300 μL FACS block buffer, containing 2% FBS in sterile 1X PBS, 
at 4º C for 15 min and centrifuged at 1000 rpm for 5 min. Cells were then incubated in  
10 μL Fc block, containing anti-CD16/32 antibody at a 1:100 dilution in sterile 1X PBS, 
at 4º C for 10 min to block nonspecific antibody binding to the cell surface. Cells were 
stained with the following antibodies: FITC CD4, PE/APC CD8a, PE CD69, APC CD25 
(eBioscience) and APC PD-1 (eBioscience). A tube of cells stained with the appropriate 
isotype controls was included. Cells were washed twice in 1 mL stain buffer (BD 
Biosciences) and resuspended in 400 μL stain buffer for analysis of extent and frequency 
of positive cells on a FACS Canto flow cytometer. 
 
Flow cytometric analysis of spleen cells: cytokine expression  
All antibodies and reagents for this section are from BDBiosciences unless 
otherwise stated. For cytokine staining, spleen cells were restimulated with 2 μL/mL Cell 
Stimulation Cocktail (eBioscience, PMA/ionomycin) and 0.6 μL/mL GolgiStop for the last 
4-6 h of culture at 37º C. Cells were then gently collected from tissue culture plates with 
25 cm cell scrapers (Sarstedt, Inc., Newton, NC, USA), washed once with stain buffer, 
and transferred to polystyrene tubes at 1X106 cells/tube for flow cytometric analysis. 
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Cells were resuspended in 300 μL FACS block buffer, containing 2% FBS in sterile 1X 
PBS, at 4ºC for 15 min and centrifuged at 1000 rpm for 5 min. Cells were then incubated 
in 10 μL Fc block, containing anti-CD16/32 antibody at a 1:100 dilution in sterile 1X 
PBS, at 4º C for 10 min to block nonspecific antibody binding to the cell surface. Cells 
were washed twice in stain buffer, resuspended in 1 mL cold Cytofix (BD Biosciences), 
and incubated for 20 min at 4ºC. Cells were centrifuged, washed twice in 1 mL stain 
buffer (BD Biosciences), resuspended in 1 mL Perm/Wash Buffer (BD Biosciences) and 
incubated for 15 min at room temperature. Cells were then centrifuged, resuspended in  
50 μL BD Perm/Wash Buffer and incubated for 30 min at room temperature with equal 
concentrations of antibodies or appropriate isotype controls: FITC CD4, APC/PE CD8a, 
PerCP-Cy5.5 IFN-γ, and PE-Cy7 IL-17A. Cells were washed twice in 1 mL BD 
Perm/Wash Buffer and resuspended in 400 μL stain buffer for analysis of extent and 
frequency of positive cells on a FACS Canto flow cytometer. 
Statistical analyses  
Data were reported using the mean as a measure of central tendency + standard 
error of the mean. To compare one variable condition between groups, a one-way 
ANOVA analysis was initially performed (GraphPad Prism version 6.03 for Windows, 
GraphPad Software, La Jolla, CA, USA). If differences were identified by the ANOVA 
analysis, a two-tailed Student’s t test was then performed to determine significance of 
differences between each of two groups (ex.: control vs. premalignant, control vs. 
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HNSCC, premalignant vs. HNSCC) using GraphPad Prism version 6.03. Significance 
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3.3 Results 
Premalignant lesion-bearing tongues release increased levels of Th-1 and Th17-
associated cytokines and chemokines compared to HNSCC-bearing and control tongues 
Previous studies have shown that immune cells infiltrating the draining lymph 
nodes of premalignant lesion-bearing mice are more activated and release increased 
levels of proinflammatory cytokines compared to HNSCC-bearing and control mice, 
suggesting that the premalignant lesion environment supports a more activated, Th1-type 
response [100]. However, the immune response at the site of the developing premalignant 
lesion of the tongue has not been extensively studied. To define the immune environment 
of premalignant lesions as they progress to HNSCC, tongues were extracted from mice 
bearing premalignant lesions or HNSCC tumors and tissue was analyzed for levels of a 
spectrum of proinflammatory cytokines and chemokines. These studies showed that 
premalignant lesion-bearing tongue tissue releases increased levels of Th1- and Th17-
associated cytokines and other proinflammatory mediators compared to HNSCC-bearing 
and control tongue tissue. As shown in Figure 3.1 below, supernatant collected from 
premalignant lesion-bearing tongue tissue cultures contained significantly increased 
levels of Th1-associated IL-2, IFN-γ, and TNF-α compared to HNSCC-bearing and 
control tongue tissue. In addition, the levels of Th17-associated IL-17A were increased in 
supernatants collected from premalignant lesion-bearing tongue tissue cultures compared 
to supernatants from HNSCC-bearing or control tongue tissue cultures, but variability of 
values among samples precluded statistical significance. Other proinflammatory 
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mediators, including GM-CSF and G-CSF (granulocyte-colony stimulating factor), were 
reduced in HNSCC-bearing tongue tissue supernatants compared to premalignant lesion-
bearing and control tongue tissue supernatants but, unlike the increased levels of other 
cytokines shown in Figure 3.1, are not increased in supernatants of premalignant lesion-
bearing tongue tissue vs. supernatants of control tongue tissue. In addition to increased 
Th1- and Th17-associated cytokines, premalignant lesion-bearing tongue tissue released 
increased levels of Th2-asociated cytokines, including IL-4, IL-6 and IL-10 compared to 
control tongue tissue, although these differences were not as significant as Th1-associated 
cytokines (data not shown). The levels of immune inhibitory TGF-β were not 
significantly different in supernatants collected from control tongue, premalignant lesion-
bearing tongue, and HNSCC tongue cultures (data not shown).  
These data show that the immune environment of tongue tissue bearing 
4-NQO-induced premalignant lesions is more proinflammatory than the immune 
environment of tongue tissue bearing established HNSCC, characterized by increased 
levels of Th1- and Th17-associated cytokines. This suggests that an active, Th1- and 
Th17-associated immune response occurs at the premalignant lesion stage, but as the 
lesion progresses to HNSCC, the response wanes significantly, possibly contributing to 
the immunosuppression evident in established HNSCC.  
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Fig. 3.1 Premalignant lesion-bearing tongues release increased levels of Th1- and 
pro-inflammatory mediators compared to HNSCC-bearing and control tongues. 
Tongues were excised from control, premalignant lesion (PM)-bearing, and 
HNSCC-bearing mice and mechanically and enzymatically digested in liberase. 
Tongue tissue was cultured for 24 h, restimulated with PMA/ionomycin for the last 
4 h of culture, and supernatants were collected for cytokine analyses by cytokine 
bead array (CBA). Data shown represent mean + standard error of the mean (SEM) of 
three independent experiments, each performed in duplicate. *p<0.05 **p<0.01      
***p<0.001 ****p<0.0001 (2-tailed Student’s t test). 
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Spleen cells produce increased levels of Th1- and Th2-associated cytokines in the 
presence of premalignant lesion-bearing tongue supernatant compared to spleen cells 
exposed to HNSCC-bearing tongue supernatant 
The premalignant and HNSCC environments are complex and are composed of 
preneoplastic and neoplastic cells, as well as infiltrating immune cells. To investigate 
how the environments shaped by premalignant lesions vs. HNSCC tumors impact on 
immune cell reactivity, supernatants from tongue tissue cultures from control, 
premalignant lesion-bearing and HNSCC-bearing mice were cultured with spleen cells 
from control C57BL/6 mice. In the presence of premalignant lesion-bearing tongue tissue 
supernatant, spleen cells produced increased levels of Th1-associated IL-2 compared to 
spleen cells in the presence of HNSCC-bearing tongue tissue supernatant (Figure 3.2). 
Upon re-stimulation with PMA/ionomycin, spleen cells produced comparable levels of 
IL-2 in the presence of control, premalignant lesion-bearing, and HNSCC-bearing tongue 
tissue supernatant, demonstrating that spleen cells are capable of producing IL-2 in all 
conditions, but they produce increased levels of IL-2 in the premalignant lesion-bearing 
tongue tissue environment without stimulation. This supports the hypothesis that the 
premalignant lesion environment is inherently more immune stimulatory than both the 
control and HNSCC environments. The level of IFN-γ produced by spleen cells in the 
premalignant lesion-bearing tongue tissue environment was increased compared to spleen 
cells in the control tongue tissue environment (p=0.053) and, to a lesser extent, spleen 
cells in the HNSCC tongue tissue environment (p=0.078). Re-stimulation with 
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PMA/ionomycin resulted in a slight increase of IFN-γ production by spleen cells in the 
premalignant lesion tongue tissue environment and a significant increase of IFN-γ 
production by spleen cells in the HNSCC tongue tissue environment. As with IL-2, these 
data show that spleen cells were capable of producing IFN-γ in all conditions, but they 
produce increased levels of IFN-γ in the premalignant lesion-bearing tongue tissue 
environment, without re-stimulation. In other words,  HNSCC tongue tissue supernatant 
alone was not enough to induce maximal IFN-γ production, but spleen cells could be 
restimulated to produce levels of IFN-γ comparable to premalignant lesion-bearing 
tongue tissue conditions.  
A similar trend was evident for the production of Th2-associated cytokines by 
spleen cells in the presence of premalignant lesion-bearing tongue tissue supernatant, 
although overall the levels of these cytokines were lower compared to Th1-associated 
cytokines (Figure 3.2). Spleen cells produced an increased level of IL-4 in the presence of 
premalignant lesion-bearing tongue tissue supernatant compared to HNSCC-bearing 
tongue tissue supernatant. However, the level of IL-4 produced by spleen cells in the 
presence of control tongue tissue supernatant was not significantly different that the level 
produced by spleen cells in premalignant lesion-bearing tongue tissue supernatant. After 
re-stimulation, the level of IL-4 produced by spleen cells in the presence of 
HNSCC-bearing tongue tissue supernatant was comparable to the level produced by 
spleen cells in the premalignant lesion tongue tissue environment, indicating that spleen 
cells were capable of producing IL-4 in the HNSCC environment after PMA/ionomycin 
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stimulation. Spleen cells produced increased levels of IL-10 in the presence of 
premalignant lesion-bearing tongue tissue supernatant compared to spleen cells in the 
presence of both HNSCC-bearing tongue tissue supernatant and control tongue tissue 
supernatant. After re-stimulation with PMA/ionomycin, the level of IL-10 produced by 
spleen cells in the premalignant lesion tongue tissue environment was increased 
compared to the level of IL-10 produced by spleen cells in the control tongue tissue 
environment and HNSCC tongue tissue environment, although the difference between the 
premalignant lesion tongue tissue environment and HNSCC tongue tissue environment 
was not significant.  
The levels of the proinflammatory mediators IL-17A and TNF-α produced by 
spleen cells were comparable in the premalignant lesion tongue tissue and HNSCC 
tongue tissue environments. Upon restimulation with PMA/ionomycin, the level of IL-
17A produced by spleen cells in the presence of premalignant lesion-bearing tongue 
tissue supernatant was decreased compared to spleen cells in the presence of HNSCC 
tongue tissue supernatant and control tongue tissue supernatant. A similar trend was 
evident for spleen cell production of TNF-α, although after re-stimulation with 
PMA/ionomycin, the level of TNF-α produced by spleen cells in the premalignant lesion-
bearing tongue tissue environment was not significantly different than the level produced 
by spleen cells in the HNSCC tongue tissue environment.  
These data support the hypothesis that the immune environment of premalignant 
lesion-bearing tongue tissue elicits increased production of Th1-associated cytokines, and 
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to a lesser degree, Th2-associated cytokines, by spleen cells compared to the immune 
environment of HNSCC-bearing tongue tissue. These data suggest that the premalignant 
lesion environment may support a more robust immune response, compared to the 
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Fig. 3.2 Spleen cells stimulated to produce increased levels of Th1- and Th2-
associated cytokines in the presence of premalignant lesion-bearing tongue tissue. 
Spleen cells from control C57BL/6 mice were cultured with media conditioned by 
tongue tissue from control, premalignant lesion (PM)-bearing, or HNSCC-bearing 
mice at a 1:10 dilution in fresh media for 72 h. Spleen cells remained unstimulated 
or were restimulated with PMA/ionomycin for the last 4 h of culture and 
supernatants were collected for cytokine analysis by cytokine bead array (CBA). 
Data shown represent mean + SEM of three independent experiments, each performed 
in duplicate.    *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001 ~p=0.053 ^^p=0.078 
(2-tailed Student’s t test). 
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Premalignant lesion cells release increased levels of proinflammatory mediators 
compared to HNSCC cells 
While the above-described studies showed the premalignant lesion environment 
to be proinflammatory and capable of stimulating immune cell cytokine production, the 
present study aimed to determine the contribution of premalignant lesion cells vs. the 
complex premalignant lesion milieu to the immune stimulatory environment. Previous 
studies have shown that both murine and human SCC cell lines and freshly isolated 
primary HNSCC tumors secrete increased levels of a panel of immune mediators, 
including IL-1α, IL-6, GM-CSF, TGF-β and PGE2 [20, 31, 34, 60, 102-104]. There has 
been little to no focus on immune mediators released by premalignant lesion cells, and 
how this compares to HNSCC cells in the 4-NQO model. To investigate this question, 
tongues were extracted from premalignant lesion-bearing and HNSCC-bearing mice to 
establish primary cell lines so that the levels of immune mediators released by the cells 
themselves could be analyzed. It was not feasible to include comparison to control tongue 
cells because normal epithelial cells do not grow in culture without added growth factor, 
which would alter the properties of the cells. Analysis of supernatants collected from the 
cell cultures showed that premalignant lesion cells secrete significantly increased levels 
of several proinflammatory mediators compared to HNSCC cells (Figure 3.3). The levels 
of G-CSF, RANTES (regulated on activation and normal T cell expressed and secreted), 
and MCP-1, while detectable in HNSCC cell supernatant, were detected in much higher 
levels in premalignant lesion cell supernatant. Of note, premalignant lesion cells released 
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significant levels of PGE2 compared to HNSCC cells. In contrast, HNSCC cell 
supernatant was characterized by increased levels of immune inhibitory TGF-β compared 
to premalignant lesion cells. These data show that the levels of immune mediators 
secreted by premalignant lesion cells vs. HNSCC cells are quite different and suggest that 
the immune environment changes as premalignant lesions progress to tumor. Further, 
these data show that premalignant lesion cells secrete significantly higher levels of 
several proinflammatory mediators compared to HNSCC cells in vitro, supporting the 
contribution of premalignant lesion cells to the immune stimulatory environment of 










 Immune Changes Associated with Progression of Premalignant Lesions to HNSCC  
Chapter 3 45                  Effect of the Premalignant Lesion and 
                                                                                          HNSCC Environments on Immune  
                                                                                                       Cell Reactivity 













Fig. 3.3 Premalignant lesion cells release increased levels of pro-inflammatory 
mediators compared to HNSCC cells in vitro. Cell lines were established from 
4-NQO-induced premalignant lesions or HNSCC tumors and grown to confluency. 
Supernatants were collected after 48 h for cytokine and chemokine analyses. Data shown 
represent 3 independent experiments performed in duplicate. *p<0.05 **p<0.01 
***p<0.001 ****p<0.0001 (2-tailed Student’s t test). 
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Spleen cells produce increased levels of innate proinflammatory mediators in the 
presence of premalignant lesion cell supernatant compared to spleen cells exposed to 
HNSCC cell supernatant or media alone 
The results in Figure 3.2 show the stimulatory effect of premalignant tongue 
tissue on normal spleen cell cytokine production, but not known is the contribution of 
premalignant lesion cells to this inflammatory immune stimulation. To investigate how 
factors produced by premalignant lesion and HNSCC tumor cells modulate the 
production of innate proinflammatory mediators by immune cells, splenocytes were 
cultured with premalignant or HNSCC cell-conditioned media, and supernatants were 
collected for cytokine and chemokine analyses. To simplify visualization of the effects of 
premalignant lesion cells vs. HNSCC cells on spleen cell cytokine production, data were 
normalized to cytokine levels secreted by spleen cells cultured in media alone (control 
cultures) and presented as fold change/control values. As shown in Figure 3.4, the levels 
of proinflammatory IL-1α and Th1-associated RANTES secreted by splenocytes in the 
presence of premalignant lesion cell supernatant were significantly increased compared to 
levels secreted by spleen cells that were incubated with HNSCC cell supernatant or 
media alone, with and without stimulation with PMA/ionomycin. The level of IL-1α 
secreted by splenocytes in the presence of premalignant lesion cell supernatant increased 
from about 40-fold/control to almost 70-fold/control after stimulation, whereas the level 
of RANTES secreted by splenocytes was about 12-fold/control with and without 
stimulation, respectively, in vitro. There were no significant differences in the levels of 
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macrophage inflammatory protein-1 alpha (MIP-1α) and macrophage inflammatory 
protein-1 beta (MIP-1β) secreted by splenocytes in the presence of premalignant and 
HNSCC supernatant, respectively, compared to control (data not shown).   
In addition to stimulating increased production of IL-1α and RANTES, 
premalignant lesion cell supernatant elicited increased production of granulocyte and 
macrophage-associated monokine induced by gamma interferon (MIG), G-CSF and 
GM-CSF from splenocytes compared to HNSCC supernatant or media alone, with and 
without stimulation. The amount of MIG secreted by splenocytes in the presence of 
premalignant cell supernatant was about 15-fold the level secreted by splenocytes in the 
presence of HNSCC cell supernatant or media alone, with and without stimulation. 
Similarly, the level of G-CSF secreted by splenocytes in the presence of premalignant 
cell supernatant was over 275-fold the level secreted by splenocytes in the presence of 
HNSCC cell supernatant or media alone. The level of GM-CSF secreted by splenocytes 
in the presence of premalignant cell supernatant was 88-fold/control, increasing to about 
140-fold/control after stimulation in vitro, whereas the level secreted by splenocytes in 
the presence of HNSCC cell supernatant was 2-fold/control, increasing to only 3-
fold/control after stimulation.  
These data show the contribution of premalignant lesion cells to inflammatory 
and immune stimulatory environment of the premalignant lesion. While premalignant 
cells stimulate a significant proinflammatory innate response, HNSCC cells are 
 Immune Changes Associated with Progression of Premalignant Lesions to HNSCC  
Chapter 3 48                  Effect of the Premalignant Lesion and 
                                                                                          HNSCC Environments on Immune  
                                                                                                       Cell Reactivity 
   
significantly less immune stimulatory. This may be a key mechanism by which the 
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Fig. 3.4 Splenocytes cultured with premalignant cell-conditioned media release 
increased levels of innate proinflammatory mediators compared to 
splenocytes cultured with HNSCC cell-conditioned media or fresh media 
alone. Splenocytes from control C57BL/6 mice were incubated with fresh 
medium or media conditioned by premalignant lesion cells or HNSCC cells, with 
or without PMA/ionomycin stimulation for the last 4 h of culture. Supernatants were 
collected from spleen cell cultures for cytokine and chemokine analyses after 72 h. 
Cytokine and chemokine levels were standardized to levels produced by spleen cells 
in media alone and data is shown as fold change/control. Data represent 3 
independent experiments, each performed in duplicate. *p<0.05 **p<0.01 ~p=0.051 
^^p=0.064 (2-tailed Student’s t test). 
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Spleen cells produce increased levels of Th1- and Th17-associated cytokines in the 
presence of premalignant lesion supernatant compared to spleen cells exposed to 
HNSCC supernatant or media alone 
The above studies showed that premalignant lesion cells elicit increased 
production of innate proinflammatory mediators from immune cells compares to HNSCC 
cells. The present study was conducted to determine the impact of premalignant lesion 
cells on stimulating the production of Th1-, Th2- and Th17-type cytokines by immune 
cells. To investigate how immune mediators produced by premalignant lesion cells and 
HNSCC cells alters T cell-associated cytokines, spleen cells were cultured with media 
conditioned by premalignant lesion cells or HNSCC cells and stained intracellularly for 
IFN-γ expression. As shown in Figure 3.5a,b below, an increased percentage of CD4+ T 
cells expressed IFN-γ in the presence of premalignant lesion cell-conditioned media 
compared to HNSCC cell-conditioned media or fresh media alone. More prominent was 
the increased percentage of CD8+ T cells that expressed IFN-γ in response to 
premalignant lesion cell-conditioned media compared to HNSCC cell-conditioned media 
or fresh media alone.  
In addition to analysis by flow cytometric staining, supernatants were collected 
from spleen cell cultures to investigate how premalignant lesion cell or HNSCC cell 
supernatants impact on the secretion of a panel of Th1-, Th2-, and Th17-associated 
cytokines. As described above, to simplify visualization of the effects of premalignant 
lesion cells vs. HNSCC cells on spleen cell cytokine production, data were normalized to 
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cytokine levels secreted by spleen cells cultured in media alone (control cultures) and 
presented as fold change/control values. As shown in Figure 3.5c, we found that the level 
of IL-2 secreted by splenocytes cultured with premalignant supernatant was significantly 
higher (20-fold/control) than splenocytes cultured with HNSCC supernatant 
(3-fold/control), after stimulation in vitro. Similarly, the levels of Th1-associated IFN-γ 
and TNF were significantly higher in the supernatant of splenocytes cultured with 
premalignant lesion cell supernatant compared to HNSCC cell supernatant, with and 
without stimulation. This data further supports the hypothesis that the premalignant 
environment supports a Th1-type response, whereas the tumor microenvironment does 
not. 
Similarly, splenocytes cultured with premalignant lesion cell supernatant 
secreted significantly higher levels of IL-17A (78-fold/control) than splenocytes 
cultured with HNSCC supernatant (1.2-fold/control), even without re-stimulation. 
After stimulation with PMA/ionomycin, the amount of IL-17A secreted by 
splenocytes in the presence of premalignant supernatant increased to over 120-
fold/control, whereas the amount of IL-17A released in the presence of HNSCC 
supernatant increased only slightly to 1.4-fold/control. This suggests that while the 
premalignant environment elicits a significant Th17-type response, the HNSCC 
environment does not.  
A similar trend was discovered with Th2-associated cytokines, although overall, 
the levels of Th2-associated cytokine were lower compared to Th1-associated cytokines. 
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The levels of IL-4 and IL-6 secreted by splenocytes cultured with premalignant lesion 
cell supernatant were significantly higher than splenocytes cultured with HNSCC cell 
supernatant or media alone. Before stimulation, the levels of IL-4 and IL-6 secreted by 
splenocytes in the presence of premalignant supernatant were increased approximately 
2-fold/control and over 150-fold/control, respectively. After stimulation in vitro, these 
levels rose to over 4-fold/control for IL-4 and decreased slightly to 130-fold/control for 
IL-6. The level of IL-10 was increased in the supernatant of splenocytes co-cultured with 
premalignant lesion cell supernatant (about 124-fold/control) compared to HNSCC cell 
supernatant (5-fold/control), although the difference was not statistically significant 
(p=0.094). After restimulation with PMA/ionomycin, the level of IL-10 produced by 
spleen cells in the presence of premalignant lesion cell supernatant (165-fold/control) was 
significantly increased compared to spleen cells in the presence of HNSCC cell 
supernatant (4-fold/control). Overall, these data indicate that premalignant lesion 
supernatant elicits a significant Th1-, Th2-, and Th17-associated response, whereas 
HNSCC supernatant is significantly less immune stimulatory.   
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Fig. 3.5 Premalignant lesion cell-conditioned media elicits increased expression 
of IFN-γ in CD4+ and CD8+ T cells and increased secretion of Th1-, Th2-, and 
Th17-associated cytokines from spleen cells compared to cytokines produced in 
HNSCC cell-conditioned media or media alone. Representative results (a) and 
graphical representation (b) of flow cytometric staining of spleen cells from control 
C57BL/6 mice cultured with media alone, premalignant lesion cell-conditioned 
media, or HNSCC cell-conditioned media for 72 h. Spleen cells were restimulated 
with PMA/ionomycin for the last 4 h of culture. Data show staining of spleen cells 
from 3 independent experiments, run in duplicate. For cytokine analyses (c), 
supernatants were collected from spleen cell cultures after 72 h and analyzed by 
CBA. Cytokine levels were standardized to levels produced by spleen cells in media 
alone and data is shown as fold change/control. Data represent mean + SEM. *p<0.05 
**p<0.01 ***p<0.001 ****p<0.0001 ~p=0.094 ^^p=0.061 (2-tailed Student’s t-test). 
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Increased percentage of CD4+ T cells express IL-2 receptor CD25 and CD8+ T cells 
express activation marker CD69 in the presence of premalignant lesion cell supernatant 
compared to expression in the presence of HNSCC cell supernatant 
The immune environment shaped by HNSCC has been shown to impact on 
immune cell activation and function [10, 20, 100, 105, 106]. Previous studies, as well as 
the current study, suggest that immune cells are more activated in the premalignant lesion 
environment [72, 100, 101]. The direct impact of immune mediators released by 
premalignant lesion cells on the activation status of immune cells, however, is not well 
defined. While the above studies showed premalignant lesion cell stimulation of spleen 
cell cytokine production, an alternate approach was used to further demonstrate T-cell 
stimulation. To further analyze how immune mediators released by premalignant lesions 
cells and HNSCC cells impact on immune cell function, the expression of IL-2 receptor 
CD25 and activation marker CD69 on spleen cells in the presence of supernatant 
collected from premalignant lesion cell and tumor cell cultures was analyzed. In the 
presence of premalignant lesion cell supernatant, an increased percentage of CD4+ T cells 
expressed CD25 compared to HNSCC cell supernatant or media alone. This increase in 
CD25 expression could reflect an increase in the percentage of T regulatory cells induced 
in the premalignant lesion environment or it could be an indicator of increased T cell 
activation. A similar trend was observed for CD8+ T cells, in which a greater percentage 
expressed CD25 in the presence of premalignant lesion cell supernatant compared to 
what was expressed in media alone, although the difference was not significant. There 
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was no difference in the expression of CD25 in the CD8+ T cell compartment between 
the premalignant lesion cell and HNSCC cell environments. In the CD4+ T cell 
compartment, the percentage of cells expressing the early activation marker CD69 in 
cultures with HNSCC cell-conditioned media was significantly decreased compared to 
cultures in media alone. In the CD8+ T cell compartment, the percentage of CD69+ cells 
was significantly increased after culture with premalignant lesion cell-conditioned media 
compared to culture with HNSCC cell-conditioned media or media alone. Further 
analysis of CD69 expression revealed an increased percentage of CD69hi-expressing cells 
among CD4+CD69+ and CD8+CD69+ T cells in cultures with premalignant lesion cell 
supernatant compared to cultures with HNSCC cell supernatant or media alone, 
suggesting that the premalignant lesion environment induces a population of highly 
activated cells in both the CD4+ and CD8+ T cell compartments (gating strategy and 
graphical results shown in Figure 3.7c,e). These data confirm the above described 
cytokine analyses by showing that the immune environment shaped by premalignant 
lesion cells is more stimulatory compared to the environment shaped by HNSCC cells 
and induces a greater percentage of activated, CD4+ T cells expressing CD25 and a 
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Fig. 3.6 Premalignant lesion cell-conditioned media elicits increased expression 
of CD25 on CD4+ T cells and CD69 on CD4+ and CD8+ T cells, compared to 
HNSCC cell-conditioned media or media alone. Representative results (a,c) and 
graphical representation (b,d) of flow cytometric staining of spleen cells from 
control C57BL/6 mice cultured with media alone, premalignant lesion 
cell-conditioned media, or HNSCC cell-conditioned media for 72 h. Data show 
staining of spleen cells from 3 independent experiments, run in duplicate. Graphical 
results of the percentage of CD69hi populations among CD4+CD69+ cells and 
CD8+CD69+ cells gated in (d) are shown in (e). Data represent mean + SEM. 
*p<0.05 **p<0.01 ***p<0.001 ~p=0.056 (2-tailed Student’s t-test). 
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Cervical lymph node cells produce increased levels of Th1-, Th2-, and Th17-associated 
cytokines and proinflammatory mediators in the presence of premalignant lesion cell 
supernatant 
In the 4-NQO model, cervical lymph nodes drain the oral cavity and therefore 
house immune cells that directly infiltrate the developing lesions and tumors [95, 97, 98, 
100]. To investigate how immune mediators produced by premalignant lesion cells and 
HNSCC cells impact on cytokine production by immune cells in the draining lymph 
nodes of the developing lesions or tumors, cervical lymph node cells were cultured with 
media conditioned by premalignant lesion cells or HNSCC cells and supernatants were 
collected for analysis by CBA. As shown in Figure 3.7, in the presence of premalignant 
lesion cell supernatant, cervical lymph node cells produced increased levels of 
Th1-associated cytokines compared to cervical lymph node cells cultured in the presence 
of HNSCC cell supernatant or media alone. This included increases in cervical lymph 
node cell production of IL-2, IFN-γ, and TNF-α in the presence of premalignant lesion 
cell supernatant compared to lymph node cell production of these Th1-type cytokines in 
the presence of HNSCC cell supernatant or media alone. A similar trend was found for 
Th2-associated cytokines, although the overall levels of Th2-associated cytokines were 
lower than Th1-associated cytokines. In the presence of premalignant lesion cell-
conditioned media, cervical lymph node cells secreted increased levels of IL-4 and IL-6 
compared to cervical lymph node cells in the presence of HNSCC cell-conditioned media 
or media alone.   
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 Similarly, cervical lymph node cells produced increased levels of the Th17 
cell-associated cytokine IL-17A and other proinflammatory mediators in the presence of 
premalignant lesion cell-conditioned media compared to levels produced by lymph node 
cells cultured with HNSCC cell-conditioned media or fresh media alone (Figure 3.7). The 
level of IL-17A produced by spleen cells in the premalignant lesion cell environment was 
higher than the level produced by spleen cells in the HNSCC cell environment or media 
alone. Cervical lymph node cells produced significantly higher levels of the chemokines 
MIP-1α and MIP-1β in the presence of premalignant lesion cell-conditioned media 
compared to when cultured in HNSCC cell-conditioned media or media alone, suggesting 
the premalignant lesion environment supports a more proinflammatory macrophage 
response compared to the HNSCC environment. The level of macrophage-supporting 
G-CSF was also higher in the supernatant of cervical lymph node cells cultured with 
premalignant lesion cell-conditioned media compared to when cultured with HNSCC 
cell-conditioned media or media alone. Overall, premalignant lesion cell supernatant 
elicits increased production of proinflammatory mediators from cervical lymph node cells 
compared to what is elicited by HNSCC cell supernatant. 
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Fig. 3.7 Cervical lymph node cells release increased levels of Th1-, Th2- and 
Th17-associated cytokines and proinflammatory mediators in the presence of 
premalignant cell-conditioned media compared levels released by lymph node 
cells in the presence of HNSCC cell-conditioned media or fresh media alone. 
Cervical lymph node cells were extracted from control C57BL/6 mice and cultured 
with premalignant lesion cell-conditioned media, HNSCC cell-conditioned media or 
media alone for 72 h. Cell cultures were restimulated with PMA/ionomycin for the 
last 4 h of culture and supernatants were collected for cytokine analyses by CBA. 
Data shown represent mean + SEM of three independent experiments, each performed 
in duplicate. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001 (2-tailed Student’s t test). 
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CHAPTER 4: ADMINISTRATION OF INDOMETHACIN TO PREMALIGNANT-
LESION BEARING MICE 
 
Aim 2: To prevent the immune skewing and tumor progression in 4-NQO-treated 
mice by inhibiting PGE2 production at the premalignant lesion stage. 
 
4.1 Introduction 
 The five-year survival rate for HNSCC patients remains at 50% [2]. Treatment for 
HNSCC patients is significantly complicated by immunosuppression and, in many cases, 
the traditional routes of therapy, including surgical resection and chemo-radiation, are 
ineffective at completely eliminating the tumor [1, 2, 20, 26, 28]. Furthermore, due to the 
location of primary tumors on the head and neck region and the effect of major surgery in 
this region, patient quality of life is often significantly decreased. There exists a critical 
need for more effective therapies, and focus has recently shifted to immunotherapies to 
reduce the burden of primary tumors and prevent recurrence.  
 The goal of any effective immunotherapy is to activate the patient’s own immune 
system to eradicate tumor. HNSCC tumors use a variety of mechanisms to evade the 
immune response, including recruitment of immunosuppressive cells, inhibition of 
cytotoxic T cells, and secretion of factors such that dampen the immune response at the 
tumor site [10, 28, 31, 32, 35, 106]. One of the factors that is upregulated in the HNSCC 
tumor environment is PGE2. While PGE2 is a proinflammatory mediator, it has also been 
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shown to directly inhibit T cell function, recruit immunosuppressive cells to the tumor 
site, skew dendritic cells toward myeloid-derived suppressor cells, and increase tumor 
growth [26, 46-49, 52, 53, 55, 60, 61]. Increased expression of COX-2, the enzyme 
responsible for increased PGE2 production by HNSCC tumors, is correlated with a worse 
prognosis in patients, suggesting that PGE2’s role in dampening the immune response at 
the tumor site plays a role in a patient’s clinical status [20, 26, 28, 60]. Previous studies 
have shown that treating HNSCC cells with COX inhibitors results in increased apoptosis 
and decreased growth of tumor cells [61]. In multiple models of murine and hamster head 
and neck cancer, administration of the COX-2-specific inhibitor celecoxib resulted in 
decreased tumor cell growth and angiogenesis [61-63]. These studies suggest that COX 
inhibition may be beneficial as a therapy for HNSCC patients. One retrospective study 
showed that HNSCC patients who had been on a regimen of COX inhibitors prior to 
surgery had increased survival rates compared to patients who had not [65], although 
neither the type of COX inhibitor nor the dosage was controlled for in this study. Several 
clinical trials have shown that administration of celecoxib to HNSCC patients as an 
adjuvant therapy resulted in significantly improved response rates [66-68]. The impact of 
COX inhibition on the immune response in HNSCC patients, however, has not been 
extensively studied. One study showed that preoperative administration of Rofecoxib, 
another COX-2-specific inhibitor, resulted in improved monocyte function, but the 
impact on T cell function or overall immune status, was not investigated [64].  
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There remains a gap in our knowledge of how COX inhibition affects the immune 
response in HSNCC patients, and specifically, how COX inhibition impacts on immune 
cell reactivity as premalignant lesions progress to tumor. Our preliminary studies in the 
4-NQO mouse model of oral carcinogenesis have shown that, despite the broad-range 
immune stimulatory and inflammatory environment of premalignant oral lesions, PGE2 is 
produced in much higher levels by premalignant lesion cells compared to what is 
produced by HNSCC cells This suggests that PGE2 may be playing a previously 
unappreciated immune-modulatory role as premalignant lesions progress to tumor. There 
may be a critical window, such as during the premalignant lesion stage, in which COX 
inhibitors can be administered to activate and direct a patient’s immune system to 
eradicate the developing tumor or to slow tumor progression. The hypothesis of the 
current study is that inhibiting PGE2 production at the premalignant lesion stage will 
skew immune cells to a Th1-associated phenotype, leading to improved clinical outcomes 
and slowing progression to tumor. 
The focus of this study is to investigate whether inhibiting PGE2 production by 
premalignant lesions results in increased activation of immune cells and if this plays a 
role in the clinical outcome of mice with 4-NQO-induced oral lesions. Treating 
premalignant lesion cells with indomethacin, a pan-COX inhibitor, resulted in increased 
induction of immune cell production of Th1-associated cytokines in vitro. To advance 
studies to be clinically relevant, indomethacin was administered to mice with 4-NQO-
induced premalignant lesions and the phenotype of immune cells infiltrating the cervical 
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lymph nodes and progression to tumor were observed (timeline shown in Figure 4.1). 
Mice receiving indomethacin at the premalignant lesion stage had significantly improved 
clinical outcomes compared to mice receiving diluent control treatment. The cervical 
lymph nodes and spleens of mice receiving indomethacin were characterized by 
increased IFN-γ expression compared to what was seen in mice receiving control 
treatment, suggesting that indomethacin plays a role in skewing immune cells to a Th1-
associated phenotype, which are part of a more effective antitumor response. 
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4.2 Materials and Methods 
Oral HNSCC carcinogenesis 
Five mg/mL 4-NQO in propylene glycol stock was diluted into the drinking water 
at a final concentration of 50 μg/mL and administered to 2-month-old female C57BL/6 
mice (Charles Rivers Laboratory, Wilmington, MA, USA) until the development of 
premalignant oral lesions (6–8 weeks) or HNSCC (12–16 weeks). To monitor lesion 
development, mice were examined endoscopically weekly using a Stryker 1.9 mm × 30° 
endoscope and images were taken using a Stryker 1088 camera (Kalamazoo, MI, USA). 
During the procedure, mice were sedated with inhaled isoflurane (Piramal Healthcare, 
Boise, ID, USA).  
 
Culture medium 
 Cell culture media consisted of 1X DMEM (Life Technologies, Grand Island, 
NY, USA) containing 4.5 g/L D-glucose and L-glutamine, supplemented with 10% fetal 
bovine serum (FBS, Sigma, St. Louis, MO, USA) and 1X antibiotic antimycotic solution 
(Sigma, St. Louis, MO, USA) containing penicillin, streptomycin and amphotericin B. To 
establish cell lines from premalignant lesions and HNSCC tumors, culture media was 
supplemented with 2X antibiotic antimycotic solution for the first 2 weeks of culture.  
 
Premalignant lesion and HNSCC cell lines  
Primary cell lines were established by excising the tongues of premalignant or 
HNSCC-bearing mice at the appropriate stage, as defined through histopathological analysis 
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by the oral pathology section in the Center for Oral Health Research at the Medical 
University of South Carolina. Premalignant lesions or HNSCC were excised from the 
tongues of 4-NQO treated mice.  To establish cell lines, premalignant lesions or HNSCC 
tumors were washed several times with PBS and antibiotic/antimycotic solutions containing 
100 mg/mL penicillin, 100 mg/mL streptomycin, and 200 mg/mL neomycin. Premalignant 
lesions or HNSCC tumors were plated on 60 mm tissue culture dishes in DMEM media 
supplemented with 10% FBS and penicillin/streptomycin/amphotericin B and cultured for 
two weeks at 37º C, replacing the media twice per week. After this period, adhering 
premalignant lesion or carcinoma cells were removed and cultured in 75 cm2 flasks in fresh 
media at 37° C, replacing the media twice per week. Prior to defining cells as 
premalignant or HNSCC, their epithelial phenotype was confirmed as well as uniformity 
of their microscopic and growth characteristics. To detach adherent cells, they were 
trypsinized, washed, and resuspended in fresh medium.  
 
Spleen processing 
Spleens were harvested from control C57BL/6 mice and homogenized using a 
glass homogenizer. Cells were passed through a 70 μm cell strainer (BD Falcon, San 
Jose, CA, USA) and rinsed with HBSS. Red blood cells were lysed by adding ACK 
Lysing Buffer (Lonza, Walkersville, MD, USA) for 3 min. Splenocytes were then washed 
twice with HBSS. Cell number was determined by counting cells excluding trypan blue 
using a hemocytometer.  
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Indomethacin treatment of premalignant lesion cells and HNSCC cells   
Premalignant lesion cells and HNSCC cells were cultured for 24 h at 37° C at 
1×106 cells/well in 12-well tissue culture plates in fresh media with or without 6 μg/mL 
indomethacin, as previously described [107]. Supernatants were collected for culture with 
spleen cells. To serve as a control for indomethacin treatment, spleen cells were cultured in 
fresh media with 6 μg/mL indomethacin. 
 
Spleen cell cultures with indomethacin-treated premalignant lesion and HNSCC cell 
supernatants 
Spleen cells from control C57BL/6 mice were cultured for 72 h at 37° C with 
supernatants collected from indomethacin-treated premalignant lesion cells and HNSCC 
cells, respectively, at 1×106 cells/well in 12-well anti-CD3-coated tissue culture plates at a 
dilution of 1:2 in fresh media containing 30 IU recombinant mouse IL-2. Controls consisted 
of splenocytes cultured for 72 h at 37° C in fresh medium, with or without 6 μg/mL 
indomethacin. Supernatants were collected and the levels of cytokines, chemokines, or 
prostaglandins produced by spleen cells were quantitated using CBAs and ELISA. The 
cytokine profile and activation status of spleen cells was analyzed by CBA and flow 
cytometric staining.   
 
Cytokine bead array 
All reagents used for the cytokine bead array are from BD Biosciences unless 
otherwise specified. The levels of IFN-γ, IL-2, IL-17A, IL-4, IL-6 and IL-10 in cell cultures 
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were determined using a mouse cytometric bead array (CBA) Th1/Th2/Th17 cytokine kit. 
Levels of IL-1α, IL-1β, IL-13, IL-12p70, IL-9, GM-CSF, G-CSF, MIG, MCP-1, MIP-1α, 
MIP-1β and RANTES in cell cultures were determined using cytometric bead array flex sets 
for the individual cytokines according to the manufacturer’s instructions. A FACS Canto 
(BD Biosciences, San Jose, CA, USA) flow cytometer was used to quantify cytokine 
profiles and relative amounts of each cytokine were analyzed using FCAP Array 
Software (manufactured by Soft Flow Hungary Ltd. for BD Biosciences, San Jose, CA, 
USA). In experiments where premalignant lesion or HNSCC supernatants were added to 
spleen cell cultures, cytokine levels in total spleen cell supernatants were adjusted for 
baseline levels in premalignant or HNSCC supernatants.  
 
Indomethacin treatment of 4-NQO-treated mice 
Two-month-old female C57BL/6 mice (Charles Rivers Laboratory, Wilmington, 
MA, USA) were administered 50 μg/mL 4-NQO in their drinking water until the 
development of premalignant oral lesions (8 weeks), as determined by weekly endoscopy 
of the oral cavities. At this time point, one group of C57BL/6 control mice (5 mice) and 
one group of premalignant lesion-bearing mice (5 mice) were euthanized and tongues and 
cervical lymph node cells were harvested for analysis. To the remaining premalignant 
lesion-bearing mice, 4-NQO water was removed and replaced with drinking water 
containing either 30 μg/mL indomethacin (10 mice) or diluent (1% ethanol) control (10 
mice) [108]. Oral cavities were endoscopically monitored weekly for the development of 
HNSCC using a Stryker 1.9 mm × 30° endoscope. Lesions were counted and scored 
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blindly every 10 days and the development of tumors was documented using a Stryker 
1088 camera. Six and twenty weeks after beginning indomethacin or diluent control 
treatment one group of mice receiving indomethacin (5 mice) and one group of mice 
receiving diluent control (5 mice) were sacrificed and tongues and cervical lymph nodes were 
harvested for analysis. A group of age-matched untreated C57BL/6 control mice were also 
sacrificed at these time points and tongues and cervical lymph nodes harvested for analysis.  
 
Lesion scoring 
As part of the endoscopic exam performed every 10 days, the total number and 
gross pathologic score of tongue lesions in 4-NQO-treated mice receiving either 
indomethacin or diluent control were blindly assessed and recorded as previously 
described [100, 109]. Lesions were scored on a 1-4 scale, with 1 indicating a flat macule, 
2 indicating a raised papule, 3 indicating a raised plaque, and 4 indicating a grossly 
exophytic lesion. 
 
Cervical lymph node processing and culture 
Cervical lymph nodes were harvested from experimental and control C57BL/6 
mice at designated time points, as described in individual experiments. Cervical lymph 
nodes were homogenized using a Stomacher 80 homogenizer (Seward) set on high for 90 
sec. Cells were then passed through a 70 μm cell strainer (BD Falcon, San Jose, CA, 
USA) and rinsed with HBSS. Cell number was determined by counting cells excluding 
trypan blue using a hemocytometer. Cells were cultured in 12-well anti-CD3-coated 
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tissue culture plates at 1X106 cells/well in fresh media for 72 h at 37º C. Supernatants 
were collected (500 μL) from each well for analysis by CBA. Cells were then 
restimulated with 2 μL/mL Cell Stimulation Cocktail (eBioscience, PMA/ionomycin) and 
0.6 μL/mL GolgiStop (BD Biosciences) for the last 4-6 h of culture at 37º C. Cells were 
gently collected from tissue culture plates with 25 cm cell scrapers (Sarstedt, Inc., 
Newton, NC, USA), washed once with stain buffer, and transferred to polystyrene tubes 
at 1X106 cells/tube for flow cytometric analysis. 
 
Flow cytometric analysis of cells 
All antibodies and reagents for this section are from BDBiosciences unless 
otherwise stated. Spleen cells or cervical lymph node cells were processed to a single cell 
suspension in polystyrene tubes at 1X106 cells/tube and were resuspended in 300 μL FACS 
block buffer, containing 2% FBS in sterile 1X PBS, at 4º C for 15 min and centrifuged at 
1000 rpm for 5 min. Cells were then incubated in 10 μL Fc block, containing anti-
CD16/CD32 antibody at a 1:100 dilution in sterile 1X PBS, at 4º C for 10 min to block 
nonspecific antibody binding to the cell surface. Cells were washed twice in stain buffer 
(BD Biosciences), resuspended in 1 mL cold BD Cytofix, and incubated for 20 min at 4º 
C. Cells were centrifuged, washed twice in 1 mL stain buffer, resuspended in 1 mL BD 
Perm/Wash Buffer and incubated for 15 min at room temperature. Cells were then 
centrifuged, resuspended in 50 μL BD Perm/Wash Buffer and incubated for 30 min at 
room temperature with equal concentrations of antibodies or appropriate isotype controls: 
FITC CD4, APC CD8a, PerCP-Cy5.5 IFN-γ and PE CD69. Cells were washed twice in   
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1 mL BD Perm/Wash Buffer and resuspended in 400 μL stain buffer for analysis of 
extent and frequency of positive cells on a FACS Canto flow cytometer. 
 
Tongue processing and culture  
Three tongues per group of mice (control untreated mice or premalignant lesion-
bearing mice treated with diluent control or indomethacin) were harvested for analysis of 
PGE2 levels by ELISA at the designated timepoints. After extraction, each tongue was 
minced and enzymatically digested using 100 μg/mL of complete liberase cocktail 
(Roche, Indianapolis, IN, USA) in 10 mL HBSS (Life Technologies, Grand Island, NY, 
USA) at 37º C for 4 h. Tissue was resuspended in 1 mL sterile PBS and lysed using an 
ultrasonic processor for 2 min. on ice. For each dissociated tongue, PGE2 levels were 
standardized to total protein. Total protein was quantitated using a BCA protein assay kit 
(Thermo Scientific, Rockford, IL, USA). 
 
Prostaglandin E2 ELISA 
To quantify PGE2 in tongue tissue, a competitive ELISA was performed 
according to the manufacturer’s instructions (Pierce Biotechnology, Rockford, IL, USA). 
Tongue tissue lysates were diluted 1:50 for analysis. Optical density at 405 nm was 
measured using a Spectra Max M2 plate reader. Concentrations of PGE2 were determined 
using SoftMax Pro 5.4.2 plate reader software. A standard concentration curve was 
generated for each independent experiment. Tongue lysate samples were tested in 
duplicate for 3 mice/group. 
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Statistical analyses  
Data were reported using the mean as a measure of central tendency + standard 
error of the mean. To compare one variable condition between groups, a one-way 
ANOVA analysis was initially performed (GraphPad Prism version 6.03 for Windows, 
GraphPad Software, La Jolla, CA, USA). If differences were identified by the ANOVA 
analysis, a two-tailed Student’s t test or Mann-Whitney U test was then performed to 
determine significance of differences between each of two groups (ex.: control vs. 
premalignant, control vs. HNSCC, premalignant vs. HNSCC, indomethacin vs. diluent 
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4.3 Results 
Indomethacin-treated premalignant lesion cells are increased in their capacity to skew 
spleen cell cytokine production  
 One mechanism by which PGE2 impacts on immune reactivity in the tumor 
environment is by inhibiting the production of Th1-associated cytokines by T cells [46-
49]. Inhibiting PGE2 production in a model of lung carcinoma resulted in a skewing of 
cytokine production by resident immune cells towards a more Th1-type phenotype 
characterized by increased IL-12 production, leading to decreased tumor growth [71]. To 
analyze how inhibiting PGE2 production impacts on cytokine production by immune cells 
in the premalignant lesion environment, and how this compares to the HNSCC 
environment, spleen cells from control C57BL/6 mice were cultured with media 
conditioned by supernatants collected from indomethacin-treated premalignant lesion 
cells or HNSCC cells. 
As shown in Figure 4.1 below, treatment of both premalignant lesion cells and 
HNSCC cells with indomethacin, a pan-COX inhibitor, significantly decreased PGE2 in 
cell culture supernatant after 24 hours. This demonstrates that indomethacin effectively 
inhibited COX enzymes in these cell cultures. Indomethacin treatment of premalignant 
lesion cells significantly increased their induction of spleen cell production of 
Th1-associated IL-2, whereas indomethacin treatment of HNSCC cells had no effect on 
the induction of spleen cell production of IL-2. Indomethacin treatment of premalignant 
lesion cells also increased their induction of spleen cell production of IFN-γ and IL-6, 
although the differences were not significant. Similar to what was observed with IL-2, 
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indomethacin treatment of HNSCC cells has no effect on the induction of IFN-γ or IL-6 
production by spleen cells. These data suggest that inhibiting PGE2 production by 
premalignant lesion cells may elicit increased production of Th1-type cytokines by 
immune cells. Interestingly, supernatants from indomethacin-treated premalignant lesion 
cells also led to increased spleen cell production of the Th2-associated cytokine IL-10 
compared to exposure to supernatants from premalignant lesion cells that were not treated 
with indomethacin, suggesting that PGE2 might be playing a role in triggering Th2-
mediated immunity as well as Th1-mediated immunity. However, the pro-tumoral vs. 
anti-tumoral implications of indomethacin are not clear. Indomethacin treatment of both 
premalignant lesion cells and HNSCC cells resulted in decreased production of IL-17A 
by spleen cells, suggesting that in both the premalignant lesion and tumor environments, 
PGE2 plays a role in maintaining Th17 cells or directly promotes IL-17A production. 
Treatment of premalignant lesion cells with indomethacin did not alter spleen cell 
expression of the IL-2 receptor CD25 or the early activation marker CD69 (data not 
shown). The given data show that indomethacin treatment of premalignant lesion cells 
skewed cytokine production by spleen cells towards a Th1-type response, which has been 
shown to be more effective against tumor.  
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Fig. 4.2 Pretreatment of premalignant lesion cells with indomethacin skews 
cytokine production by splenocytes, leading to increased production of Th1-
associated IL-2 and decreased production of Th17-associated IL-17A. (a) 
Premalignant lesion cells and HNSCC cells were plated at 1X106 cells/well and 
treated with 6 μg/mL indomethacin for 24 h. The levels of PGE2 in cell supernatants 
were analyzed by ELISA. (b) Spleen cells from control C57BL/6 mice were cultured 
for 72 h with media conditioned by supernatants from premalignant lesion cell or 
HNSCC cell cultures that remained untreated or were previously treated with 6 μg/mL 
indomethacin. Supernatants were collected for cytokine analysis by CBA. Cytokine 
levels were standardized to levels produced by spleen cells in media alone and data is 
shown as fold change/control. Data represent 5 independent experiments, each run in 
duplicate. Data represent mean + SEM. *p<0.05 **p<0.01 ***p<0.001     
****p<0.0001 (2-tailed Student’s t-test). 
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions 
results in an improved clinical response compared to diluent control treatment 
The goal of any effective immunotherapy is to improve clinical outcome. The 
current study aimed to stimulate immune cell reactivity and slow progression to tumor by 
administering indomethacin to mice at the premalignant lesion stage. To monitor the 
development of premalignant lesions to HNSCC in mice treated with indomethacin vs. 
diluent control, mice were endoscoped every 10 days, beginning at the premalignant 
lesion stage. The lesions were scored on a 1-4 scale, with 1 representing a flat macule, 
and 4 representing a grossly exophytic tumor. As shown in Figure 4.3a below, mice 
receiving indomethacin treatment beginning at the premalignant lesion stage had a 
significantly better overall clinical outcome compared to diluent control mice. At the 
endpoint of the study (day 139, about 20 weeks post-initiation of treatment), the average 
lesion score for mice receiving indomethacin was 1.9, whereas the average lesion score 
for mice receiving diluent control was 3.4. Differences in clinical outcome were more 
striking at later time points, as shown in Figure 4.3. There were no significant differences 
in lesion stage between the diluent control and indomethacin groups until the last time 
point (day 139 post-initiation of treatment), although by day 104, the average lesion score 
for mice receiving diluent control treatment (2.5) was higher than mice receiving 
indomethacin treatment (2.1). By the endpoint of the study (day 139) two mice in the 
diluent control group progressed to advanced HNSCC (4), bearing exophytic tumors, 
whereas no mice in the indomethacin group progressed to this stage during the study. 
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Furthermore, 4 out of 5 mice in the diluent control group had lesions scores of 3 or higher 
at the endpoint of the study, compared to one mouse in the indomethacin group. These 
data show that administering indomethacin to mice with 4-NQO-induced premalignant 
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Fig. 4.3 Administering indomethacin to mice with 4-NQO-induced premalignant 
lesions improves clinical outcome and slows progression to HNSCC. (a) 
Indomethacin or diluent control was administered in the drinking water of mice with 
4-NQO-induced premalignant oral lesions. Oral cavities of mice were endoscoped 
every 10 days and lesions were scored 1-4. Lesion scores for each mouse at 
representative time points are shown in (b). Images of the oral cavity of a 
representative mouse from each group are shown in (c). Lesion score data represent 
mean + SEM. Shown in (b) and (c) are scores for mice endoscoped at baseline and at 
days 13 (1.9 wks), 33 (4.7 wks), 70 (10 wks), 104 (14.9 wks) and 139 (19.9 wks) after 
initiating indomethacin treatment. *p<0.05 (Mann-Whitney U test). 
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions leads 
to increased activation of cervical lymph node cells 20 weeks post-onset of treatment, 
compared to that of diluent control treatment 
 Since the above studies showed an improved clinical response in mice receiving 
indomethacin beginning at the premalignant lesion stage and other studies have shown 
that inhibiting PGE2 leads to increased immune reactivity in the tumor environment [71], 
we sought next to investigate whether indomethacin treatment impacted on immune cell 
reactivity in our model. To investigate whether indomethacin treatment of mice with 
premalignant lesions skews cytokine production by immune cells in vivo, cervical lymph 
node cells were extracted from 4-NQO-treated mice receiving indomethacin or diluent 
control treatments 6 weeks and 20 weeks post-onset of treatment and immunostained by 
flow cytometry. As shown in Figure 4.4a below, the percentage and total number of T 
cells expressing IFN-γ was not significantly different between the indomethacin and 
diluent control treatment groups 6 weeks post-onset of treatment, although the total 
number of CD8+IFN-γ+ T cells was increased in cervical lymph nodes of mice receiving 
indomethacin compared to control C57BL/6 mice (p=0.059). The percentage of T cells 
expressing the activation marker CD69 was not significantly different between the 
indomethacin and diluent control treatment groups. At 20 weeks post-initiation of 
treatment, the percentage of CD8+ T cells expressing IFN-γ in the cervical lymph nodes 
of mice receiving indomethacin was increased compared to mice receiving diluent 
control treatment, although the difference was not significant. The total number of 
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CD8+IFN-γ+ T cells was increased in the cervical lymph nodes of mice receiving 
indomethacin (p=0.066) and mice receiving diluent control treatment (p=0.034), 
compared to control mice. Although the percentage of T cells expressing CD69 was not 
different between the indomethacin and diluent control groups, the total numbers of 
CD4+CD69+ and CD8+CD69+ T cells in the cervical lymph nodes of mice in the 
indomethacin-treated group was increased compared to that in the untreated control 
group, although the differences were not statistically significant (p=0.087, p=0.099). 
While indomethacin treatment of mice with 4-NQO-induced premalignant lesions did not 
result in statistically significant changes in the number of CD4+ or CD8+ cells expressing 
IFN-γ, it caused a progressive tendency toward an increase in the number of CD8+ T cells 
expressing IFN-γ and this tendency became more prominent with a more prolonged 
period of indomethacin treatment. This suggests that indomethacin may play a role in 
skewing cytokine production towards a Th1-type response by immune cells as 
premalignant oral lesion progress to HNSCC. 
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Fig. 4.4 Administering indomethacin to mice with 4-NQO-induced premalignant 
lesions tends to increase the number of IFN-γ-expressing CD8+ T cells and CD69-
expressing CD4+ and CD8+ T cells at 20 weeks post-onset of treatment. Graphical 
representation of flow cytometric staining of cervical lymph node cells extracted from 
mice with 4-NQO-induced oral lesions receiving indomethacin or diluent control 
treatment 6 weeks post-onset of treatment (a,b) and 20 weeks post-onset of treatment 
(c,d). For intracellular cytokine staining, cells were stimulated with PMA/ionomycin 
for the last 4 h of culture. Five mice were examined for each group per time point. 
Total number of positive cells was calculated by multiplying percent positive cells by 
the number of cervical lymph node cells for each mouse. Data represent mean + SEM. 
*p<0.05 (2-tailed Student’s t-test). 
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions 
results in increased production of IFN-γ by spleen cells at 6 and 20 weeks post-onset of 
treatment 
 Inhibiting PGE2 production has been shown to have immune stimulatory effects 
in several animal models of cancer and chronic infection [71, 110-112]. The above 
studies suggested a shift toward Th1-skewed immune cells in the cervical lymph nodes of 
premalignant lesion-bearing mice treated with indomethacin. To determine if 
indomethacin treatment induces a systemic Th1-type response in mice with 
4-NQO-induced premalignant lesions, cytokine production by spleen cells from mice 
receiving indomethacin or diluent control treatments was analyzed by cytokine bead 
array. IL-2 production by spleen cells was not significantly affected by indomethacin or 
diluent control treatments 6 weeks or 20 weeks post-onset of treatment (shown in Figure 
4.5 below). However, the level of IFN-γ produced by spleen cells in mice receiving 
indomethacin was increased compared to the level produced by spleen cells of diluent 
control-treated mice. Importantly, while the level of IFN-γ produced by spleen cells in 
mice receiving diluent control treatment was lower than the level produced by spleen 
cells of untreated control mice, the level of IFN-γ produced by spleen cells in mice 
receiving indomethacin was actually greater than control values, suggesting that 
indomethacin does play a role in inducing a systemic, Th1-type response. The level of 
IL-17A produced by spleen cells of mice receiving indomethacin was decreased 
compared to the level produced by spleen cells of mice receiving diluent control and 
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untreated control mice both 6 weeks and 20 weeks post-onset of treatment. The level of 
proinflammatory TNF-α produced by spleen cells of indomethacin-treated mice receiving 
indomethacin was increased compared to the levels produced by spleen cells of either 
diluent-treated mice or from untreated mice 6 weeks post-onset of treatment (p=0.073), 
although this difference was not evident 20 weeks post-onset of treatment. Overall, these 
data suggest that administering indomethacin to mice with 4-NQO-induced oral lesions 
can skew immune responses toward a systemic Th1-type response. 
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Fig. 4.5 Administering indomethacin to mice with 4-NQO-induced premalignant 
lesions increases spleen cell production of IFN-γ 6 weeks and 20 weeks post-onset 
of treatment. Spleens from mice receiving indomethacin or diluent control 
treatments were extracted at 6 weeks and 20 weeks post-onset of treatment. Spleen 
cells were cultured for 72 h at 1X106 cells/well and supernatants were collected for 
analysis by CBA. Five mice were examined for each group per time point. Spleen 
cells from untreated C57BL/6 mice served as controls. Cytokine levels were analyzed 
as fold change from values for controls. Data represent mean + SEM. *p<0.05          
(2-tailed Student’s t-test). 
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APPENDIX 
Cervical lymph nodes of mice with 4-NQO induced premalignant lesions contain an 






Fig. S4.1 Cervical lymph nodes of mice with 4-NQO induced premalignant 
lesions contain an increased percentage of CD8+CD69+ cells. Graphical 
representation of flow cytometric staining of cervical lymph node cells extracted 
from mice with 4-NQO-induced premalignant oral lesions. For intracellular cytokine 
staining, cells were stimulated with PMA/ionomycin for the last 4h of culture. Five 
mice were examined for each group per time point. Total number of positive cells 
was calculated by multiplying percent positive cells by the number of cervical lymph 
node cells for each mouse. Data represent mean + SEM. *p<0.05 (2-tailed Student’s 
t-test). 
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions 












Fig. S4.2 Administering indomethacin to mice with 4-NQO-induced 
premalignant lesions decreases levels of PGE2 in tongue tissue 6 weeks post-onset 
of treatment. Tongues from mice receiving indomethacin or diluent control 
treatments were extracted at baseline, 6 weeks and 20 weeks post-onset of treatment. 
Tongue tissue was mechanically and enzymatically digested using a liberase cocktail. 
Tongue tissue was lysed and levels of PGE2 in lysates were determined by ELISA 
after diluting samples 1:50. Levels of PGE2 were normalized to tissue protein levels. 
Data represent 3 mice per group per time point, run in duplicate. Data represent mean 
+ SEM. *p<0.05 (2-tailed Student’s t-test). 
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions 
results in an increase in total cervical lymph node cell count 6 weeks and 20 weeks 











Fig. S4.3 Administering indomethacin to mice with 4-NQO-induced 
premalignant lesions increases the total number of cervical lymph node cells 6 
and 20 weeks post-initiation of treatment. Cervical lymph nodes from mice 
receiving indomethacin or diluent control treatments were extracted at baseline, 6 
weeks and 20 weeks post-initiation of treatment. Cells were processed to single cell 
suspensions and total number of trypan blue-excluding cells were counted. Data 
represent 5 mice per group per time point. Data represent mean + SEM.        
*p<0.05 (2-tailed Student’s t-test). The total number of cervical lymph node cells 
in mice receiving diluent control treatment decreased from 6 to 20 weeks 
post-initiation of treatment (^^p=0.07). 
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions does 





Fig. S4.4 Administering indomethacin to mice with 4-NQO-induced 
premalignant lesions does not impact on the total number of CD4+ or CD8+ T 
cells within cervical lymph nodes. Graphical representation of flow cytometric 
staining of cervical lymph node cells extracted from mice with 4-NQO-induced oral 
lesions receiving indomethacin or diluent control treatment 6 weeks post-onset of 
treatment (a) and 20 weeks post-onset of treatment (b). Five mice were examined for 
each group per time point. Total number of positive cells was calculated by 
multiplying percent positive cells by the number of cervical lymph node cells for each 
mouse. Data represent mean + SEM. *p<0.05 **p<0.01 (2-tailed Student’s t-test). 
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CHAPTER 5: GENERAL DISCUSSION 
5.1 HNSCC Tumors Suppress Immune Cell Reactivity 
HNSCC patients are characterized by immunosuppression, both systemically and 
at the site of the tumor [8-12]. This remains one of the most challenging obstacles for 
treatment and research has turned toward the development of immunotherapies aimed at 
reactivating a patient’s immune system against the tumor. A critical part of developing an 
effective immunotherapy is understanding the mechanisms by which developing HNSCC 
tumors evade the immune response, which is the focus of the current study.  
The process of tumor escape can be divided into three major phases [18, 113]. In 
the first stage, elimination, transformed cells are recognized by circulating immune cells 
and an inflammatory response is initiated to eliminate the dysplastic tissue. If any 
remaining malignant cells persist, the equilibrium stage begins, which can last for many 
years [18]. Though infiltrating immune cells recognize the dysplastic tissue and mount a 
robust proinflammatory response, the tumor persists. The final stage, tumor escape, is 
characterized by a loss of MHC expression by HNSCC cells and direct secretion of 
immune-modulating factors [19-23]. Tumor-infiltrating T cells exhibit a number of 
functional defects, including decreased proliferation in response to IL-2, decreased 
expression of the CD3 ζ chain, and an imbalanced cytokine profile, marked by 
significantly decreased IL-2 and IFN-γ secretion; in short, they exhibit a less activated 
Th1 phenotype that is not effective against tumor [105, 106].  
Primary tumors from HNSCC patients have been shown to secrete a panel of 
immune-modulating factors, including IL-6, IL-10, GM-CSF, TGF-β and PGE2 [10, 20, 
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28, 31, 34-36, 103, 104]. The role of each of these factors in the tumor environment is 
complex, as factors typically associated with a proinflammatory immune response are 
harnessed by the tumor for growth and angiogenesis. Tumor-secreted IL-6 and IL-10 
promote a Th2-type response at the site of the tumor, which has been shown to be less 
effective at eliminating a growing tumor and actually contributes to tumor growth by 
recruiting a population of immunosuppressive T regulatory cells and skewing the 
environment away from a more proinflammatory, antitumor Th1-type response [20, 28-
30]. Increased levels of GM-CSF at the site of HNSCC tumors have been associated with 
an increased infiltration of MDSCs and a worse prognosis in patients [10, 35]. HNSCC 
tumors also harness factors secreted by infiltrating immune cells. MDSC-derived IL-6 
has been shown to promote tumor angiogenesis [33]. Even factors such as IFN-γ, 
secreted by T cells, have been shown to contribute to Th17 cell differentiation and 
increased tumor growth [114, 115]. Increased expression of COX-2, the enzyme 
responsible for increased PGE2 production by HNSCC tumors, is also associated with 
increased tumor growth and a poorer prognosis in patients [20, 26, 28, 36, 60]. Although 
PGE2 contributes to neutrophil recruitment during the early stages of inflammation and 
infection, it has been shown to directly inhibit CD8+ T cell function in the tumor 
environment [39-41, 46-48]. It is well established that factors secreted by HNSCC cells 




 Immune Changes Associated with Progression of Premalignant Lesions to HNSCC  
Chapter 5 96                                        General Discussion            
   
5.2 Inflammatory Environment of Premalignant Lesions 
While many studies have focused on the mechanisms by which established 
HNSCC tumors evade an effective immune response, less focus has been given to what 
the present study has shown to be a stage in which an inflammatory immune response is 
active, and yet unsuccessful at eliminating, the dysplastic tissue, i.e. the premalignant 
lesion stage. At what point does the inflammatory environment shaped by a robust 
immune response turn towards a tumor-promoting mechanism? Is there a point, before 
the tumor becomes established, that the immune response can be rescued to slow 
progression to tumor?  
A few studies have shown that premalignant oral lesions in patients are 
characterized by increased levels of proinflammatory mediators, including IL-6 and 
IL-17A, compared to HNSCC tumor tissue, but these studies are based on a low number 
of patients and do not delve into the mechanism by which mediators released by the 
lesions themselves impact on immune cell reactivity [72-74]. The current study uses the 
4-NQO mouse model of oral carcinogenesis to investigate how the immune environment 
of premalignant lesions differs from that of established HNSCC, and more specifically, 
how factors secreted by premalignant lesion cells modulate the immune response and 
how this interaction leads to persistence of the tumor vs. eradication of the dysplastic 
tissue. Preliminary studies in the 4-NQO model  have shown that the cervical lymph 
nodes of premalignant lesion-bearing mice are characterized by increased numbers of 
proinflammatory T cells (Th17 cells) and proinflammatory cytokines and chemokines 
(IL-17A, MIP-1α, MIP-1β) compared to that seen in HNSCC-bearing and control mice, 
suggesting that immune cells are more activated in the premalignant lesion environment 
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[100]. The current study shows that tongue tissue from mice with 4-NQO-induced 
premalignant lesions releases increased levels of Th1-and Th17-associated cytokines, 
including IL-2, IFN-γ, TNF-α, and IL-17A compared to what is released from tongue 
tissue from HNSCC-bearing and control mice. This indicates that the environment of 
premalignant lesions, at the site of the tongue itself, is more proinflammatory compared 
to the environment of established tumors, and suggests that the premalignant lesion 
environment supports a more robust, Th1-type response compared to the HNSCC 
environment.  
When spleen cells from control C57BL/6 mice were cultured with media 
conditioned by premalignant lesion-bearing tongue tissue, they produced significantly 
increased levels of Th1- and Th2-associated cytokines, including IL-2, IL-4, and IL-10, 
compared to spleen cells cultured with media conditioned by HNSCC-bearing tongue 
tissue or media alone. This data indicates that the environment of premalignant 
lesion-bearing tongue tissue is more immune stimulatory than HNSCC-bearing tongue 
tissue. An interesting observation from this study is that after re-stimulation with 
PMA/ionomycin, spleen cells produced comparable levels of both Th1- and 
Th2-associated cytokines in both the premalignant lesion and HNSCC environments, 
demonstrating that 1) Premalignant lesion-bearing tongue tissue is inherently more 
immune stimulatory than HNSCC-bearing tongue tissue and 2) Spleen cells can be 
stimulated to produce increased levels of these cytokines in the HNSCC environment, so 
the cells are not inherently defective. It is somewhat perplexing that premalignant lesion-
bearing tongue tissue elicited increased production of both Th1-associated cytokines such 
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as IL-2 and Th2-associated cytokines such as IL-10, which typically play a more 
immunosuppressive role. This could suggest that the environment shaped by 
premalignant lesions stimulates both Th1-type and Th2-type cells. Alternatively, the 
increase in Th2-type cytokines may instead be the result of an initial dramatic increase in 
Th1-type proinflammatory cytokines as a mechanism to “turn off” the cycle of 
inflammation. In this way, the premalignant lesion state represents a battle of immune 
cells secreting proinflammatory mediators to eliminate the dysplastic tissue against 
immunosuppressive cells secreting immune inhibitory molecules to dampen 
inflammation, which ultimately can lead to the establishment of HNSCC. As the current 
study demonstrates, HNSCC-bearing tongue tissue does not elicit a significant Th1- or 
Th2-type response from immune cells because by the time the tumor is established, the 
battle has essentially been lost. 
For the current study, a holistic in vitro approach was chosen to investigate how 
mediators released by premalignant lesion-bearing vs. HNSCC-bearing tongue tissues 
impact on spleen cell cytokine production. Because of the muscular nature of the tongue 
and the mechanical and enzymatic methods of tongue digestion, harvesting a sufficient 
population of live immune cells from tongue tissue for analysis of cytokine production is 
not feasible. To account for secretion of cytokines and other immune mediators during 
the digestion process, cytokine levels in spleen cell cultures were adjusted for baseline 
levels in tongue tissue and all tongues were digested by identical means, so the results 
could be interpreted clearly. Overall, the data demonstrate that the environment of a 
developing premalignant lesion is more proinflammatory and elicits increased production 
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of cytokines by immune cells compared to the environment of an established HNSCC 
tumor. To further delve into the question of how the premalignant lesion vs. HNSCC 
environment impacts on immune cell cytokine production, future studies could culture 
isolated T cell subsets (CD4+, CD8+, Foxp3+) with media conditioned by tongue tissue 
from premalignant lesion-bearing and control mice. This could more precisely tease out 
the effects of the premalignant lesion environment skewing of CD4+ vs. CD8+ T cells and 
offer insight into how the premalignant lesion environment impacts on proinflammatory 
vs. immunosuppressive immune cells.  
5.3 Mediators Secreted by Premalignant Lesion Cells 
Dissecting how premalignant lesion cells and HNSCC cells themselves contribute 
to the immune environment, and how this impacts on infiltrating immune cells, is 
difficult for many reasons, one of which is the complexity of a developing tumor. 
Premalignant lesions, as they develop into tumors, consist of a complex network of cells, 
including epithelial cells, endothelial cells, fibroblasts, stromal cells, smooth muscle 
cells, infiltrating immune cells, and cells that are transforming or have become malignant 
[27].  
The present study initiated the dissection of the premalignant lesion by 
establishing primary cultures of premalignant lesion cells and HNSCC cells. These cells 
were then used to define the immune mediators produced directly by premalignant lesion 
and HNSCC cells as well as their impact on immune cells, as they also contribute to the 
lesion and tumor environments. This study shows that premalignant lesion cells 
established from mice with 4-NQO-induced lesions secrete significantly higher levels of 
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several immune mediators, including MCP-1, RANTES, G-CSF, and PGE2, compared to 
HNSCC cells. While the levels of these mediators were detectable in the supernatant of 
HNSCC cells, as a few previous studies using human and murine HNSCC cell lines have 
indicated [60, 102-104], they were detected in much higher levels in the supernatant of 
premalignant lesion cells. These data bring to light a new observation: premalignant 
lesion cells themselves produce high levels of several proinflammatory mediators. The 
data suggest that the proinflammatory environment of premalignant lesion-bearing 
tongues and increased infiltration of proinflammatory cells into the draining lymph nodes 
of premalignant lesion-bearing mice observed in the 4-NQO model may be a direct 
consequence of the environment set up by the premalignant lesion cells themselves.  
To address the question of how proinflammatory mediators produced by 
premalignant lesion cells might impact on immune cell cytokine production, spleen cells 
or cervical lymph node cells were cultured with media conditioned by premalignant 
lesion cells, HNSCC cells, or media alone. Premalignant lesion cell-conditioned media 
elicited significantly increased production of innate proinflammatory mediators as well as 
Th1-, Th2-, and Th17-associated cytokines by spleen cells and cervical lymph node cells 
compared to HNSCC cell-conditioned media or media alone. Analysis by flow 
cytometric staining showed that an increased percentage of CD4+ and CD8+ T cells 
expressed IFN-γ and an increased percentage of CD8+ T cells expressed the early 
activation marker CD69 in the presence of premalignant lesion-conditioned media 
compared to what was expressed in the presence of HNSCC cell-conditioned media or 
media alone. Furthermore, among both CD4+ and CD8+ T cells, a striking 
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CD69hi- expressing population was observed in the presence of premalignant lesion-
conditioned media compared to what was observed in the presence of HNSCC cell-
conditioned media or media alone. The data shows that mediators released by 
premalignant lesion cells skew immune cells toward a more activated, Th1-like 
phenotype and also skew secretion of cytokines. This suggests that, at the cellular level, 
premalignant lesion cells promote an activated, Th1-type response and set up a cycle of 
inflammation at the site of the developing lesion. 
The current study is based on cell cultures established from 4-NQO-induced 
premalignant lesions or HNSCC tumors. Therefore, one consideration is whether 
culturing the cells in vitro may lead to the production of a different panel of cytokines or 
chemokines, which may not reflect the in vivo phenotype. To account for changes in 
phenotype over the periods of culture and ensure consistency, the baseline levels of 
cytokines and chemokines in collected supernatants were analyzed for each experiment. 
The strength of establishing cell cultures from premalignant lesions and HNSCC tumors, 
is that the cytokine and chemokine environment set up by the cells themselves (vs. 
surrounding tissue), can be defined, which offers valuable insight into how premalignant 
lesions might be modulating the immune response as they progress to tumor. 
5.4 Role of PGE2 in the Progression of Premalignant Lesions to HNSCC  
While the role of several immune mediators, such as PGE2, has been studied in 
the HNSCC environment, their role in the premalignant lesion environment has not been 
defined. Previous studies have shown that PGE2 is upregulated in HNSCC tumors, and 
increased levels of PGE2 have been associated with decreased levels of cytotoxic T cells 
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increased levels of immunosuppressive cells at the tumor site [20, 28, 36, 60]. Increased 
levels of COX-2, the inducible enzyme responsible for the increased PGE2 production, in 
HNSCC tumors has also been associated with a worse prognosis in patients [26, 36]. In 
other models of cancer, PGE2 has been shown to play an immunosuppressive role, by 
promoting the secretion of Th2-associated IL-10, inhibiting production of IL-2 by T cells, 
and supporting a population of immunosuppressive cells at the site of the tumor [46-53, 
55]. In a model of lung carcinoma, inhibiting PGE2 production led to a shift in cytokine 
production by T cells towards a more Th1-type response and decreased tumor burden 
[71].  
In the current study, it was found that premalignant lesion cells secrete 
significantly increased levels of PGE2 compared to HNSCC cells. This is paradoxical 
given the immune stimulatory and inflammatory environment of premalignant lesions. 
The current study aimed to determine the pro-tumor vs. anti-tumor role of PGE2 as 
premalignant lesions progress to HNSCC. We hypothesized that inhibition of PGE2 
production at the premalignant lesion stage may skew T cell cytokine production towards 
a more Th1-type response, rather than a broad state of activation and inflammation, and 
lead to improved clinical outcomes. In vitro, pretreatment of premalignant lesion cells 
with indomethacin, a pan-COX inhibitor, resulted in increased induction of spleen cell 
production of Th1-associated IL-2. Indomethacin treatment of HNSCC cells had minimal 
effect on their induction of spleen cell cytokine production, suggesting that treatment at 
the premalignant stage may be optimal to reactivate a Th1-type immune response. 
Administration of indomethacin in the drinking water of mice with 4-NQO-induced 
premalignant lesions resulted in reduced tumor burden and significantly improved 
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clinical outcomes compared to that seen for diluent control-treated mice. At the endpoint 
of the study, 4 out of 5 mice in the diluent control group had progressed to lesion scores 
of 3 or higher (bearing raised plaques or grossly exophytic lesions or tumors) whereas 
only one mouse had progressed to a lesion score of 3 in the indomethacin group. Analysis 
of cervical lymph nodes revealed that CD8+ T cells in mice that had received 
indomethacin expressed increased levels of IFN-γ compared to levels expressed by 
lymph node cells of mice that had received diluent control treatment at 20 weeks 
post-onset of treatment, although the results were not significant. Interestingly, the levels 
of IFN-γ secreted by spleen cells were also significantly increased in mice that had 
received indomethacin treatment compared to what was secreted by spleen cells of mice 
that had received diluent control treatment, suggesting that indomethacin may play a role 
in activating a systemic, Th1-type response that slows progression to tumor. 
The results of this study offer insight into how PGE2 modulates the immune 
response at the premalignant lesion stage. Previous studies have looked at the effect of 
inhibiting PGE2 production in tumors and have suggested that PGE2 plays a role in 
supporting T regulatory cells and promoting a Th2-type response [26, 38, 69-71]. The 
current study suggests that PGE2 may also be playing an immunosuppressive role before 
a tumor becomes established, as inhibiting PGE2 production by premalignant lesion cells 
resulted in increased production of IL-2 by spleen cells in vitro. However, inhibiting 
premalignant lesion cell production of PGE2 also led to an increased production of IL-10 
in vitro, so the effect of indomethacin treatment cannot be classified singularly as 
“pro-Th1.” The concurrent increase in IL-10 may be explained as a consequence of an 
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initial increase in Th1-type cytokines, similar to what was observed with spleen cells 
cultured with premalignant lesion cell-conditioned media alone. In vivo, administration of 
indomethacin to mice beginning at the premalignant lesion stage resulted in significantly 
improved clinical outcomes and increased production of IFN-γ by immune cells, 
compared to what was seen for diluent control treatment. Interestingly, spleen cells from 
mice that had received indomethacin secreted higher levels of IFN-γ at both 6 and 20 
weeks post-onset of treatment compared to what was produced by spleen cells of mice 
that had received diluent control treatment, suggesting that indomethacin could promote a 
systemic, Th1-type response as lesions progress to tumor. Overall, the results suggest that 
inhibiting PGE2 production at the premalignant lesion stage is advantageous to an 
improved clinical outcome.  
The current study adds valuable insight into the role of IL-17A, and Th17 cells, as 
premalignant lesions progress to HNSCC. The role for Th17 cells in HNSCC 
carcinogenesis, as with many other cancers, has not been completely defined. Some 
studies have indicated they play a pro-tumoral role by promoting tumor angiogenesis and 
growth in models of head and neck cancer as well as pancreatic neoplasia and skin cancer 
[114, 116-118]. Other studies in both head and neck cancer and models of pancreatic 
cancer suggest that they are part of a beneficial, antitumor response and promote tumor 
cell apoptosis [116, 119]. PGE2 has been shown to play a role in sustaining Th17 cells in 
the tumor environment through the IL-23 axis [120]. But how PGE2 impacts on Th17 
cells in the premalignant environment has not been defined. By inhibiting PGE2 
production at the premalignant lesion stage, the current study offers insight into the 
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PGE2-Th17 cell axis as premalignant lesions progress to HNSCC. In vitro, inhibiting the 
production of PGE2 by premalignant lesion cells and HNSCC cells led to decreased 
production of IL-17A by spleen cells. This supports previous work implicating PGE2 as a 
key player in sustaining Th17 cells in the HNSCC environment, but also suggests a novel 
role for PGE2 in promoting the secretion of IL-17A by Th17 cells, in both the 
premalignant lesion and HNSCC environments. Furthermore, spleen cells from mice that 
had received indomethacin at the premalignant lesion stage produced decreased levels of 
IL-17A ex vivo compared to IL-17A production by spleen cells of mice that had received 
diluent control treatment, suggesting that a decrease in PGE2 in the lesion and developing 
tumor environment may lead to a systemic decrease in IL-17A secretion by Th17 cells. 
The current study offers evidence to support the hypothesis that Th17 cells play a 
pro-tumoral role as premalignant lesions progress to tumor, as inhibiting PGE2 
production at the premalignant lesion stage reduced production of IL-17A by spleen cells 
and led to significantly improved clinical outcomes.  
Future studies with larger cohorts of mice will be necessary to investigate the role 
of PGE2 in modulating Th17 cells as premalignant lesions progress to tumor. In the 
current study, the number of cervical lymph node cells was not sufficient to detect levels 
of cytokine section by CBA. To investigate the secretion of IL-17A by cells closer to the 
site of the lesion and developing tumor, future studies could focus on the intracellular 
expression of IL-17A by cervical lymph node cells over the course of indomethacin 
treatment. Future studies might also investigate the role of IL-23 as a downstream 
mediator of PGE2 in sustaining Th17 cells in the premalignant lesion environment by 
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administering an IL-23 inhibitor along with a COX inhibitor to mice with 4-NQO-
induced premalignant lesions.  
One weakness of the current study is that the treatment groups consisted of five 
mice each, making statistical analysis more difficult. Future studies based on larger 
cohorts of mice will more clearly delineate differences in cytokine production between 
treatment groups. This may also allow pooling of cervical lymph node cells among 
treatment groups for analysis by CBA. In the current study, indomethacin, a pan-COX 
inhibitor, was administered to mice through their drinking water, a mode of COX 
inhibition that has been established in other mouse models of cancer [108, 121]. This 
method is convenient, and in the case of oral cancer, allows treatment to be administered 
at the site of the lesion and developing tumor. However, as shown in Supplementary 
Figure S4.1, the levels of PGE2 in the supernatants of tongue tissue from mice that had 
received indomethacin were moderately decreased 6 weeks post-onset of treatment 
compared to mice that had received diluent control treatment and only minimally 
decreased 20 weeks post-onset of treatment. This may be a consequence of the digestion 
method, which damages the tissue and may promote the release of PGE2 from endothelial 
cells, fibroblasts, lesion cells, tumor cells and other cells in the tongue. Another 
explanation is that because a majority of mice had progressed past the premalignant 
lesion stage by the endpoint of the study and the level of PGE2 produced by HNSCC 
tumor cells is significantly reduced compared to the level produced by premalignant 
lesion cells, differences induced by indomethacin treatment may not be as striking in the 
later stages of tumor development. In the future, analyzing PGE2 levels in the plasma 
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may offer insight into how indomethacin impacts systemic levels of PGE2 as 
premalignant lesions progress to tumor. Future studies might also investigate how 
COX-2-specific inhibition, through administration of celecoxib, impacts on immune cell 
reactivity and clinical outcome as premalignant lesions progress to tumor. In this way, the 
role of PGE2 in skewing the immune response at the premalignant lesion stage can be 
further delineated.  
5.5 Closing Remarks 
 Oral cancer is a unique malignancy, in that it can be diagnosed when tissue first 
becomes dysplastic and presents as leukoplakias or erythroplakias developing on the 
tongue and floor of mouth. By the time HNSCC becomes established, patients exhibit 
local and systemic signs of immunosuppression, making treatment more difficult and 
increasing the chance of recurrence. By diagnosing oral lesions before they develop into 
established HNSCC and administering immunotherapies to activate a patient’s immune 
response, treatment may become more effective for these patients.  
 The current study offers evidence that significant immune changes are occurring 
before HNSCC becomes established, at the premalignant lesion stage. Premalignant 
lesion cells established from mice with 4-NQO-induced lesions secrete a host of 
mediators, including proinflammatory chemokines and PGE2, and elicit increased 
production of proinflammatory cytokines by immune cells compared to HNSCC cells. 
Overall, the premalignant lesion environment is more immune stimulatory than the 
HNSCC environment. The role of PGE2 in the premalignant lesion environment, 
however, has not been previously defined. Previous studies have shown that HNSCC 
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tumors are characterized by increased levels of PGE2, which has been associated with a 
decreased infiltration of T cells at the site of the tumor and a worse prognosis in patients. 
Administration of COX inhibitors as adjuvant therapy to HNSCC patients has resulted in 
improved clinical outcomes. However, the current study shows that PGE2 is produced in 
much higher levels by premalignant lesion cells compared to HNSCC cells, suggesting it 
may be playing an immune-modulating role well before HNSCC is established. 
Therefore, intervening with treatment to skew the response towards a more effective 
Th1-type antitumor response may be more beneficial at the premalignant lesion stage, 
when the battle against the dysplastic tissue is first being fought. The current study offers 
evidence to support this view, as administration of indomethacin, a COX inhibitor, to 
mice with 4-NQO-induced premalignant lesions led to increased production of Th1-type 
cytokines by T cells, significantly improved clinical outcomes and slowed progression to 
tumor. Overall, the current study shows that significant immune changes are occurring 
much earlier in the progression of HNSCC than has been previously appreciated and 
suggests that administration of immunotherapies, such as COX-2 inhibitors, at the 
premalignant lesion stage may boost the immune response against tumor and improve 
clinical outcomes for patients.
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